US20070148662A1 - Prostate-specific membrane antigen - Google Patents
Prostate-specific membrane antigen Download PDFInfo
- Publication number
- US20070148662A1 US20070148662A1 US11/480,319 US48031906A US2007148662A1 US 20070148662 A1 US20070148662 A1 US 20070148662A1 US 48031906 A US48031906 A US 48031906A US 2007148662 A1 US2007148662 A1 US 2007148662A1
- Authority
- US
- United States
- Prior art keywords
- prostate
- antigen
- specific membrane
- mammalian
- psm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title claims abstract description 196
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title claims abstract description 48
- 239000003446 ligand Substances 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 62
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 48
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 48
- 230000009261 transgenic effect Effects 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 108020004414 DNA Proteins 0.000 claims description 42
- 108020004999 messenger RNA Proteins 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 13
- 210000004962 mammalian cell Anatomy 0.000 claims description 13
- 102000053602 DNA Human genes 0.000 claims description 7
- 108020004491 Antisense DNA Proteins 0.000 claims description 4
- 239000003816 antisense DNA Substances 0.000 claims description 4
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 abstract description 38
- 230000014509 gene expression Effects 0.000 abstract description 35
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 34
- 239000000427 antigen Substances 0.000 abstract description 34
- 102000036639 antigens Human genes 0.000 abstract description 34
- 108091007433 antigens Proteins 0.000 abstract description 34
- 239000013598 vector Substances 0.000 abstract description 24
- 239000012528 membrane Substances 0.000 abstract description 22
- 210000002307 prostate Anatomy 0.000 abstract description 19
- 238000003384 imaging method Methods 0.000 abstract description 17
- 239000002773 nucleotide Substances 0.000 abstract description 14
- 125000003729 nucleotide group Chemical group 0.000 abstract description 14
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 9
- 239000002254 cytotoxic agent Substances 0.000 abstract description 9
- 231100000599 cytotoxic agent Toxicity 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 238000003018 immunoassay Methods 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 102000046689 human FOLH1 Human genes 0.000 description 149
- 210000004027 cell Anatomy 0.000 description 83
- 108090000623 proteins and genes Proteins 0.000 description 49
- 239000013615 primer Substances 0.000 description 46
- 239000002299 complementary DNA Substances 0.000 description 44
- 206010028980 Neoplasm Diseases 0.000 description 37
- 102000004196 processed proteins & peptides Human genes 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 239000003053 toxin Substances 0.000 description 14
- 231100000765 toxin Toxicity 0.000 description 14
- 108700012359 toxins Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000010367 cloning Methods 0.000 description 9
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 8
- 108010033576 Transferrin Receptors Proteins 0.000 description 8
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012216 imaging agent Substances 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000000211 autoradiogram Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000707152 Homo sapiens SH2B adapter protein 1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150005926 Pc gene Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000798098 Rattus norvegicus Serotransferrin Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 108010054176 apotransferrin Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000009073 conformational modification Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000025352 lymph node carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003854 type 2 muscle cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
Definitions
- Prostate cancer represents the second leading cause of death from cancer in man (1).
- prostatic cancer is the leading site for cancer development in men.
- the difference between these two facts relates to prostatic cancer occurring with increasing frequency as men age, especially in the ages beyond 60 at a time when death from other factors often intervenes.
- the spectrum of biologic aggressiveness of prostatic cancer is great, so that in some men following detection the tumor remains a latent histologic tumor and does not become clinically significant, whereas in other it progresses rapidly, metastasizes and kills the man in a relatively short 2-5 year period (1, 2).
- prostatic acid phosphatase PAP
- prostate specific antigen PSA
- PAP was one of the earliest serum markers for detecting metastatic spread (3). PAP hydrolyses tyrosine phosphate and has a broad substrate specificity. Tyrosine phosphorylation is often increased with oncogenic transformation. It has been hypothesized that during neoplastic transformation there is less phosphatase activity available to inactivate proteins that are activated by phosphorylation on tyrosine residues. In some instances, insertion of phosphatases that have tyrosine phosphatase activity has reversed the malignant phenotype.
- PSA is a protease and it is not readily appreciated how loss of its activity correlates with cancer development (4, 5).
- the proteolytic activity of PSA is inhibited by zinc. Zinc concentrations are high in the normal prostate and reduced in prostatic cancer. Possibly the loss of zinc allows for increased proteolytic activity by PSA.
- proteases are involved in metastasis and some proteases stimulate mitotic activity, the potentially increased activity of PSA could be hypothesized to play a role in the tumors metastases and spread (6).
- PSA and PAP are found in prostatic secretions. Both appear to be dependent on the presence of androgens for their production and are substantially reduced following androgen deprivation.
- Prostate-specific membrane antigen which appears to be localized to the prostatic membrane has been identified. This antigen was identified as the result of generating monoclonal antibodies to a prostatic cancer cell, LNCaP (7).
- Dr. Horoszewicz established a cell line designated LNCaP from the lymph node of a hormone refractory, heavily pretreated patient (8). This line was found to have an aneuploid human male karyotype. It maintained prostatic differentiation functionality in that it produced both PSA and PAP. It possessed an androgen receptor of high affinity and specificity. Mice were immunized with LNCaP cells and hybridomas were derived from sensitized animals. A monoclonal antibody was derived and was designated 7E11-C5 (7). The antibody staining was consistent with a membrane location and isolated fractions of LNCaP cell membranes exhibited a strongly positive reaction with immunoblotting and ELISA techniques.
- This antibody did not inhibit or enhance the growth of LNCaP cells in vitro or in vivo.
- the antibody to this antigen was remarkably specific to prostatic epithelial cells, as no reactivity was observed in any other component. Immunohistochemical staining of cancerous epithelial cells was more intense than that of normal or benign epithelial cells.
- Dr. Horoszewicz also reported detection of immunoreactive material using 7E11-C5 in serum of prostatic cancer patients (7).
- the immunoreactivity was detectable in nearly 60% of patients with stage D-2 disease and in a slightly lower percentage of patients with earlier stage disease, but the numbers of patients in the latter group are small.
- Patients with benign prostatic hyperplasia (BPH) were negative.
- Patients with no apparent disease were negative, but 50-60% of patients in remission yet with active stable disease or with progression demonstrated positive serum reactivity.
- Patients with non prostatic tumors did not show immunoreactivity with 7E11-C5.
- the 7E11-C5 monoclonal antibody is currently in clinical trials.
- the aldehyde groups of the antibody were oxidized and the linker-chelator glycol-tyrosyl-(n, ⁇ -diethylenetriamine-pentacetic acid)-lysine (GYK-DTPA) was coupled to the reactive aldehydes of the heavy chain (9).
- GYK-DTPA linker-chelator glycol-tyrosyl-(n, ⁇ -diethylenetriamine-pentacetic acid)-lysine
- the resulting antibody was designated CYT-356. Immunohistochemical staining patterns were similar except that the CYT-356 modified antibody stained skeletal muscle. The comparison of CYT-356 with 7E11-C5 monoclonal antibody suggested both had binding to type 2 muscle fibers.
- a 100 kd glycoprotein unique to prostate cells and tissues was purified and characterized.
- the protein was digested proteolytically with trypsin and nine peptide fragments were sequenced.
- PCR polymerase chain reaction
- the full-length 2.65 kilobase (kb) cDNA coding for this antigen was cloned.
- Preliminary results have revealed that this antigen is highly expressed in prostate cancer tissues, including bone and lymph node metastases (12).
- the entire DNA sequence for the cDNA as well as the predicted amino acid sequence for the antigen was determined.
- FIG. 1 Signal in lane 2 represent the 100 kD PSM antigen.
- the EGFr was used as the positive control and is shown in lane 1.
- Incubation with rabbit antimouse (RAM) antibody alone served as negative control and is shown in lane 3.
- RAM rabbit antimouse
- FIG. 2 Upper two photos show LNCaP cytospins staining positively for PSM antigen. Lower left in DU-145 and lower right is PC-3 cytospin, both negative for PSM antigen expression.
- FIG. 3 Upper two panels are human prostate sections (BPH) staining positively for PSM antigen.
- the lower two panels show invasive prostate carcinoma human sections staining positively for expression of the PSM antigen.
- FIG. 4 100 kD PSM antigen following immunoprecipitation of 35 S-Methionine labelled LNCaP cells with Cyt-356 antibody.
- FIG. 5 3% agarose gels stained with Ethidium bromide revealing PCR products obtained using the degenerate PSM antigen primers.
- the arrow points to sample IN-20, which is a 1.1 kb PCR product which we later confirmed to be a partial cDNA coding for the PSM gene.
- FIG. 6 2% agarose gels of plasmid DNA resulting from TA cloning of PCR products. Inserts are excised from the PCR II vector (Invitrogen Corp.) by digestion with EcoRI. 1.1 kb PSM gene partial cDNA product is shown in lane 3 of gel 1.
- FIG. 7 Autoradiogram showing size of cDNA represented in applicants' LNCaP library.
- FIG. 8 Restriction analysis of full-length clones of PSM gene obtained after screening cDNA library. Samples have been cut with Not I and Sal I restriction enzymes to liberate the insert.
- FIG. 9 Plasmid Southern autoradiogram of full length PSM gene clones. Size is approximately 2.7 kb.
- FIG. 10 Northern blot revealing PSM expression limited to LNCaP prostate cancer line and H26 Ras-transfected LNCaP cell line.
- PC-3, DU-145, T-24, SKRC-27, HELA, MCF-7, HL-60, and others were are all negative.
- FIG. 11 Autoradiogram of Northern analysis revealing expression of 2.8 kb PSM message unique to the LNCaP cell line (lane 1), and absent from the DU-145 (lane 2) and PC-3 cell lines (lane 3). RNA size ladder is shown on the left (kb), and 28S and 18S ribosomal RNA bands are indicated on the right.
- FIG. 12 Results of PCR of human prostate tissues using PSM gene primers. Lanes are numbered from left to right. Lane 1, LNCaP; Lane 2, H26; Lane 3, DU-145; Lane 4, Normal Prostate; Lane 5, BPH; Lane 6, Prostate Cancer; Lane 7, BPH; Lane 8, Normal; Lane 9, BPH; Lane 10, BPH; Lane 11, BPH; Lane 12, Normal; Lane 13, Normal; Lane 14, Cancer; Lane 15, Cancer; Lane 16, Cancer; Lane 17, Normal; Lane 18, Cancer; Lane 19, IN-20 Control; Lane 20, PSM cDNA
- FIG. 13 Isoelectric point of PSM antigen (non-glycosylated)
- FIG. 14 Secondary structure of PSM antigen
- FIG. 15 A Hydrophilicity plot of PSM antigen B. Prediction of membrane spanning segments
- FIG. 16 Homology with chicken, rat and human transferrin receptor sequence
- This invention provides an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane (PSM) antigen.
- the isolated mammalian nucleic acid may be DNA, cDNA or RNA.
- This invention also provides nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding the PSM antigen.
- the nucleic acid molecule may either be DNA or RNA.
- This invention provides nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule which is complementary to the nucleic acid molecule encoding a mammalian prostate-specific membrane antigen.
- This invention further provides a method of detecting expression of the PSM antigen which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with a labelled PSM antigen specific nucleic acid molecule under hybridizing conditions, determining the presence of mRNA hybridized to the probe, and thereby detecting the expression of the PSM antigen by the cell.
- the PSM antigen in tissue sections may be similarly detected.
- This invention provides isolated nucleic acid sequence of PSM antigen operatively linked to a promoter of RNA transcription.
- This invention further provides a vector which comprises an isolated mammalian nucleic acid molecule of PSM antigen.
- This invention further provides a host vector system for the production of a polypeptide having the biological activity of a mammalian PSM antigen which comprises the vector comprising the mammalian nucleic acid molecule encoding a mammalian PSM antigen and a suitable host.
- the suitable host for the expression of PSM antigen may be a bacterial cell, insect cell, or mammalian cell.
- This invention also provides a method of producing a polypeptide having the biological activity of a mammalian PSM antigen which comprises growing the host cell of vector system having a vector comprising the isolated mammalian nucleic acid molecule encoding a mammalian PSM antigen and a suitable host under suitable conditions permitting production of the polypeptide and recovery of the polypeptide so produced.
- This invention provides a method for determining whether a ligand can bind to a mammalian PSM antigen which comprises contacting a mammalian cell having an isolated mammalian DNA molecule encoding a mammalian PSM antigen with the ligand under conditions permitting binding of ligands to the mammalian PSM antigen, and determining whether the ligand binds to a mammalian PSM antigen.
- This invention further provides ligands which bind to PSM antigen.
- This invention provides purified mammalian PSM antigen.
- This invention also provides a polypeptide encoded by the isolated mammalian nucleic acid molecule encoding a mammalian PSM antigen.
- This invention further provides a method to identify and purify ligands of mammalian PSM antigen.
- This invention further provides a method to produce both polyclonal and monoclonal antibody using purified PSM antigens or polypeptides encoded by an isolated mammalian nucleic acid molecule encoding a mammalian PSM antigen.
- This invention provides polyclonal and monoclonal antibody most likely but not limited to directed either to peptide Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 35), or Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 36) or Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 37) of the PSM antigen.
- This invention provides a therapeutic agent comprising an antibody directed against a mammalian PSM antigen and a cytotoxic agent conjugated thereto.
- This invention also provides a method of imaging prostate cancer in human patients which comprises administering to the patient at least one antibody directed against PSM antigen, capable of binding to the cell surface of the prostate cancer cell and labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface PSM antigen.
- This invention further provides a composition comprising an effective imaging amount of the antibody directed against PSM antigen and a pharmaceutically acceptable carrier.
- This invention further provides a method of imaging prostate cancer in human patients which comprises administering to the patient multiple antibodies directed towards different PSM epitopes.
- the invention also provides a method of imaging prostate cancer in human patients which comprises administering to the patient at least one ligand, capable of binding to the cell surface of the prostate cancer cell and labelled with an imaging agent under conditions so as to form a complex between the ligand and the cell surface PSM antigen.
- This invention further provides a composition comprising an effective imaging amount of PSM antigen and a pharmaceutically acceptable carrier.
- This invention provides an immunoassay for measuring the amount of the PSM antigen in a biological sample, e.g. serum, comprising steps of a) contacting the biological sample with at least one PSM antibody to form a complex with said antibody and the PSM antigen, and b) measuring the amount of PSM antigen in said biological sample by measuring the amount of said complex.
- a biological sample e.g. serum
- This invention also provides an immunoassay for measuring the amount of the PSM antigen in a biological sample comprising steps of a) contacting the biological sample with at least one PSM ligand to form a complex with said ligand and the PSM antigen, and b) measuring the amount of the PSM antigen in said biological sample by measuring the amount of said complex.
- This invention provides a method to purify mammalian PSM antigen comprising steps of:
- This invention further provides transgenic nonhuman mammals which comprises an isolated nucleic acid molecule of PSM antigen.
- This invention also provides a transgenic nonhuman mammal whose genome comprises antisense DNA complementary to DNA encoding a mammalian PSM antigen so placed as to be transcribed into antisense mRNA complementary to mRNA encoding the PSM antigen and which hybridizes to mRNA encoding the PSM antigen thereby reducing its translation.
- references to specific nucleotides are to nucleotides present on the coding strand of the nucleic acid.
- the following standard abbreviations are used throughout the specification to indicate specific nucleotides:
- This invention provides an isolated mammalian nucleic acid encoding a mammalian prostate-specific membrane (PSM) antigen.
- PSM prostate-specific membrane
- This invention further provides an isolated mammalian DNA molecule of an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen.
- This invention also provides an isolated mammalian cDNA molecule encoding a mammalian prostate-specific membrane antigen.
- This invention provides an isolated mammalian RNA molecule encoding a mammalina prostate-specific membrane antigen.
- the isolated nucleic sequence is cDNA from human as shown in sequence ID number 1.
- GenBank Los Alamos National Laboratory, Los Alamos, N. Mex.
- PSM Homo sapiens
- This invention also encompasses DNAs and cDNAs which encode amino acid sequences which differ from those of PSM antigen, but which should not produce phenotypic changes.
- this invention also encompasses DNAs and cDNAs which hybridize to the DNA and cDNA of the subject invention. Hybridization methods are well known to those of skill in the art.
- the DNA molecules of the subject invention also include DNA molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms.
- These molecules include: the incorporation of codons “preferred” for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.
- the DNA molecules described and claimed herein are useful for the information which they provide concerning the amino acid sequence of the polypeptide and as products for the large scale synthesis of the polypeptide by a variety of recombinant techniques.
- the molecule is useful for generating new cloning and expression vectors, transformed and transfected prokaryotic and eukaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide and related products.
- isolated mammalian nucleic acid molecules encoding a mammalian prostate-specific membrane antigen are useful for the development of probes to study the tumorigenesis of prostate cancer.
- This invention also provides nucleic acid molecules of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule encoding the prostate-specific membrane antigen.
- This nucleic acid molecule produced can either be DNA or RNA.
- the phrase “specifically hybridizing” means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its own and to form double-helical segments through hydrogen bonding between complementary base pairs.
- This nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule encoding the prostate-specific membrane antigen can be used as a probe.
- Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe.
- DNA probe molecules may be produced by insertion of a DNA molecule which encodes PSM antigen into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable bacterial host cells, replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers.
- RNA probes may be generated by inserting the PSM antigen molecule downstream of a bacteriophage promoter such as T3, T7 or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with the linearized PSM antigen fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase.
- This invention also provides a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule which is complementary to the mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen.
- This molecule may either be a DNA or RNA molecule.
- the current invention further provides a method of detecting the expression of a mammalian PSM antigen expression in a cell which comprises obtaining total mRNA from the cell, contacting the mRNA so obtained with a labelled nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of the nucleic acid molecule encoding a mammalian PSM antigen under hybridizing conditions, determining the presence of mRNA hybridized to the molecule and thereby detecting the expression of the mammalian prostate-specific membrane antigen in the cell.
- the nucleic acid molecules synthesized above may be used to detect expression of a PSM antigen by detecting the presence of mRNA coding for the PSM antigen.
- Total mRNA from the cell may be isolated by many procedures well known to a person of ordinary skill in the art.
- the hybridizing conditions of the labelled nucleic acid molecules may be determined by routine experimentation well known in the art.
- the presence of mRNA hybridized to the probe may be determined by gel electrophoresis or other methods known in the art. By measuring the amount of the hybrid made, the expression of the PSM antigen by the cell can be determined.
- the labelling may be radioactive.
- one or more radioactive nucleotides can be incorporated in the nucleic acid when it is made.
- nucleic acids are extracted by precipitation from lysed cells and the mRNA is isolated from the extract using an oligo-dT column which binds the poly-A tails of the mRNA molecules (13).
- the mRNA is then exposed to radioactively labelled probe on a nitrocellulose membrane, and the probe hybridizes to and thereby labels complementary mRNA sequences. Binding may be detected by luminescence autoradiography or scintillation counting.
- other methods for performing these steps are well known to those skilled in the art, and the discussion above is merely an example.
- This invention further provides another method to detect expression of a PSM antigen in tissue sections which comprises contacting the tissue sections with a labelled nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of nucleic acid molecules encoding a mammalian PSM antigen under hybridizing conditions, determining the presence of mRNA hybridized to the molecule and thereby detecting the expression of the mammalian PSM antigen in tissue sections.
- the probes are also useful for in-situ hybridization or in order to locate tissues which express this gene, or for other hybridization assays for the presence of this gene or its mRNA in various biological tissues.
- the in-situ hybridization using a labelled nucleic acid molecule is well known in the art.
- tissue sections are incubated with the labelled nucleic acid molecule to allow the hybridization to occur.
- the molecule will carry a marker for the detection because it is “labelled”, the amount of the hybrid will be determined based on the detection of the amount of the marker and so will the expression of PSM antigen.
- This invention further provides isolated PSM antigen nucleic acid molecule operatively linked to a promoter of RNA transcription.
- the isolated PSM antigen sequence can be linked to vector systems.
- Various vectors including plasmid vectors, cosmid vectors, bacteriophage vectors and other viruses are well known to ordinary skilled practitioners.
- This invention further provides a vector which comprises the isolated nucleic acid molecule encoding for the PSM antigen.
- insert and vector DNA can both be exposed to a restriction enzyme to create complementary ends on both molecules which base pair with each other and are then ligated together with DNA ligase.
- linkers can be ligated to the insert DNA which correspond to a restriction site in the vector DNA, which is then digested with the restriction enzyme which cuts at that site.
- Other means are also available and known to an ordinary skilled practitioner.
- the PSM sequence is cloned in the Not I/Sal I site of pSPORT/vector (Gibco®-BRL).
- This plasmid, p55A-PSM was deposited on Aug. 14, 1992 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. Plasmid, p55A-PSM, was accorded ATCC Accession Number 75294.
- This invention further provides a host vector system for the production of a polypeptide having the biological activity of the prostate-specific membrane antigen. These vectors may be transformed into a suitable host cell to form a host cell vector system for the production of a polypeptide having the biological activity of PSM antigen.
- a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG (14).
- a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome.
- Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art, for example the methods described above for constructing vectors in general. Expression vectors are useful to produce cells that express the PSM antigen.
- This invention further provides an isolated DNA or cDNA molecule described hereinabove wherein the host cell is selected from the group consisting of bacterial cells (such as E. coli ), yeast cells, fungal cells, insect cells and animal cells.
- bacterial cells such as E. coli
- yeast cells such as E. coli
- fungal cells such as E. coli
- insect cells such as E. coli
- animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CV1 cells and various primary mammalian cells.
- This invention further provides a method of producing a polypeptide having the biological activity of the prostate-specific membrane antigen which comprising growing host cells of a vector system containing the PSM antigen sequence under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.
- This invention provides a mammalian cell comprising a DNA molecule encoding a mammalian PSM antigen, such as a mammalian cell comprising a plasmid adapted for expression in a mammalian cell, which comprises a DNA molecule encoding a mammalian PSM antigen and the regulatory elements necessary for expression of the DNA in the mammalian cell so located relative to the DNA encoding the mammalian PSM antigen as to permit expression thereof.
- a mammalian cell comprising a DNA molecule encoding a mammalian PSM antigen, such as a mammalian cell comprising a plasmid adapted for expression in a mammalian cell, which comprises a DNA molecule encoding a mammalian PSM antigen and the regulatory elements necessary for expression of the DNA in the mammalian cell so located relative to the DNA encoding the mammalian PSM antigen as to permit expression thereof.
- mammalian cells may be used as hosts, including, but not limited to, the mouse fibroblast cell NIH3T3, CHO cells, HeLa cells, Ltk ⁇ cells, Cos cells, etc.
- Expression plasmids such as that described supra may be used to transfect mammalian cells by methods well known in the art such as calcium phosphate precipitation, electroporation or DNA encoding the mammalian PSM antigen may be otherwise introduced into mammalian cells, e.g., by microinjection, to obtain mammalian cells which comprise DNA, e.g., cDNA or a plasmid, encoding a mammalian PSM antigen.
- This invention provides a method for determining whether a ligand can bind to a mammalian prostate-specific membrane antigen which comprises contacting a mammalian cell comprising an isolated DNA molecule encoding a mammalian prostate-specific membrane antigen with the ligand under conditions permitting binding of ligands to the mammalian prostate-specific membrane antigen, and thereby determining whether the ligand binds to a mammalian prostate-specific membrane antigen.
- This invention further provides ligands bound to the mammalian PSM antigen.
- This invention also provides a therapeutic agent comprising a ligand identified by the above-described method and a cytotoxic agent conjugated thereto.
- the cytotoxic agent may either be a radioisotope or a toxin. Examples of radioisotopes or toxins are well known to one of ordinary skill in the art.
- This invention also provides a method of imaging prostate cancer in human patients which comprises administering to the patients at least one ligand identified by the above-described method, capable of binding to the cell surface of the prostate cancer cell and labelled with an imaging agent under conditions permitting formation of a complex between the ligand and the cell surface PSM antigen.
- This invention further provides a composition comprising an effective imaging agent of the PSM antigen ligand and a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers are well known to one of ordinary skill in the art.
- such a pharmaceutically acceptable carrier can be physiological saline.
- purified mammalian PSM antigen a purified mammalian PSM antigen.
- purified prostate-specific membrane antigen shall mean isolated naturally-occurring prostate-specific membrane antigen or protein (purified from nature or manufactured such that the primary, secondary and tertiary conformation, and posttranslational modifications are identical to naturally-occurring material) as well as non-naturally occurring polypeptides having a primary structural conformation (i.e. continuous sequence of amino acid residues).
- polypeptides include derivatives and analogs.
- a method to identify the ligand comprises a) coupling the purified mammalian PSM antigen to a solid matrix, b) incubating the coupled purified mammalian PSM protein with the potential ligands under the conditions permitting binding of ligands and the purified PSM antigen; c) washing the ligand and coupled purified mammalian PSM antigen complex formed in b) to eliminate the nonspecific binding and impurities and finally d) eluting the ligand from the bound purified mammalian PSM antigen.
- the above method may also be used to purify ligands from any biological source.
- cell lysates, serum or other biological samples will be used to incubate with the mammalian PSM antigen bound on a matrix. Specific natural ligand will then be identified and purified as above described.
- antigenic areas may be identified and antibodies directed against these areas may be generated and targeted to the prostate cancer for imaging the cancer or therapies.
- This invention provides an antibody directed against the amino acid sequence of a mammalian PSM antigen.
- This invention provides a method to select specific regions on the PSM antigen to generate antibodies.
- the protein sequence may be determined from the PSM DNA sequence.
- Amino acid sequences may be analyzed by methods well known to those skilled in the art to determine whether they produce hydrophobic or hydrophilic regions in the proteins which they build. In the case of cell membrane proteins, hydrophobic regions are well known to form the part of the protein that is inserted into the lipid bilayer of the cell membrane, while hydrophilic regions are located on the cell surface, in an aqueous environment. Usually, the hydrophilic regions will be more immunogenic than the hydrophobic regions. Therefore the hydrophilic amino acid sequences may be selected and used to generate antibodies specific to mammalian PSM antigen.
- hydrophilic sequences of the human PSM antigen shown in hydrophilicity plot of FIG. 15A may be easily selected.
- the selected peptides may be prepared using commercially available machines.
- DNA such as a cDNA or a fragment thereof, may be cloned and expressed and the resulting polypeptide recovered and used as an immunogen.
- Polyclonal antibodies against these peptides may be produced by immunizing animals using the selected peptides.
- Monoclonal antibodies are prepared using hybridoma technology by fusing antibody producing B cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody.
- monoclonal antibodies may be produced by in vitro techniques known to a person of ordinary skill in the art. These antibodies are useful to detect the expression of mammalian PSM antigen in living animals, in humans, or in biological tissues or fluids isolated from animals or humans.
- peptides Asp-Glu-Leu-Lys-Ala-Glu SEQ ID No. 35
- Asn-Glu-Asp-Gly-Asn-Glu SEQ ID No. 36
- Lys-Ser-Pro-Asp-Glu-Gly SEQ ID No. 37
- This invention further provides polyclonal and monoclonal antibody(ies) against peptides Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 35), Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 36) and Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 37).
- This invention provides a therapeutic agent comprising antibodies or ligand(s) directed against PSM antigen and a cytotoxic agent conjugated thereto or antibodies linked enzymes which activate prodrug to kill the tumor.
- the cytotoxic agent may either be a radioisotope or toxin.
- This invention provides a method of imaging prostate cancer in human patients which comprises administering to the patient the monoclonal antibody directed against the peptide of the mammalian PSM antigen capable of binding to the cell surface of the prostate cancer cell and labeled with an imaging agent under conditions permitting formation of a complex between the monoclonal antibody and the cell surface prostate-specific membrane antigen.
- the imaging agent is a radioisotope such as Indium 111 .
- This invention further provides a prostate cancer specific imaging agent comprising the antibody directed against PSM antigen and a radioisotope conjugated thereto.
- This invention also provides a composition comprising an effective imaging amount of the antibody directed against the PSM antigen and a pharmaceutically acceptable carrier.
- the methods to determine effective imaging amounts are well known to a skilled practitioner. One method is by titration using different amounts of the antibody.
- This invention further provides an immunoassay for measuring the amount of the prostate-specific membrane antigen in a biological sample comprising steps of a) contacting the biological sample with at least one antibody directed against the PSM antigen to form a complex with said antibody and the prostate-specific membrane antigen, and b) measuring the amount of the prostate-specific membrane antigen in said biological sample by measuring the amount of said complex.
- the biological sample is a serum sample.
- This invention provides a method to purify mammalian prostate-specific membrane antigen comprising steps of a) coupling the antibody directed against the PSM antigen to a solid matrix; b) incubating the coupled antibody of a) with lysate containing prostate-specific membrane antigen under the condition which the antibody and prostate membrane specific can bind; c) washing the solid matrix to eliminate impurities and d) eluting the prostate-specific membrane antigen from the coupled antibody.
- This invention also provides a transgenic nonhuman mammal which comprises the isolated nucleic acid molecule encoding a mammalian PSM antigen.
- This invention further provides a transgenic nonhuman mammal whose genome comprises antisense DNA complementary to DNA encoding a mammalian prostate-specific membrane antigen so placed as to be transcribed into antisense mRNA complementary to mRNA encoding the prostate-specific membrane antigen and which hybridizes to mRNA encoding the prostate specific antigen thereby reducing its translation.
- Animal model systems which elucidate the physiological and behavioral roles of mammalian PSM antigen are produced by creating transgenic animals in which the expression of the PSM antigen is either increased or decreased, or the amino acid sequence of the expressed PSM antigen is altered, by a variety of techniques.
- Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding a mammalian PSM antigen, by microinjection, electroporation, retroviral transfection or other means well known to those skilled in the art, into appropriate fertilized embryos in order to produce a transgenic animal (16) or 2) Homologous recombination (17) of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these PSM antigen sequences.
- the technique of homologous recombination is well known in the art.
- transgenic animal One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as M2 medium (16).
- DNA or cDNA encoding a mammalian PSM antigen is purified from a vector by methods well known in the art.
- Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the trans-gene.
- tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the trans-gene.
- microinjection needle which may be made from capillary tubing using a pipet puller
- the egg to be injected is put in a depression slide.
- the needle is inserted into the pronucleus of the egg, and the DNA solution is injected.
- the injected egg is then transferred into the oviduct of a pseudopregnant mouse (a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant), where it proceeds to the uterus, implants, and develops to term.
- pseudopregnant mouse a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant
- PSM antigen sequence Another use of the PSM antigen sequence is to isolate homologous gene or genes in different mammals.
- the gene or genes can be isolated by low stringency screening of either cDNA or genomic libraries of different mammals using probes from PSM sequence.
- the positive clones identified will be further analyzed by DNA sequencing techniques which are well known to an ordinary person skilled in the art. For example, the detection of members of the protein serine kinase family by homology probing (18).
- the approach for cloning the gene involved purification of the antigen in large quantities by immunoprecipitation, and microsequencing of several internal peptides for use in synthesizing degenerate oligonucleotide primers for subsequent use in the polymerase chain reaction (19, 20).
- a partial cDNA was amplified as a PCR product and this was used as a homologous probe to clone the full-length cDNA molecule from a LNCaP (Lymph Node Carcinoma of Prostate) cell line cDNA plasmid library (8).
- LNCaP Lymph Node Carcinoma of Prostate
- Membrane proteins were isolated from cells by hypotonic lysis followed by centrifugation over a sucrose density gradient (21). 10-20 ⁇ g of LNCaP, DU-145, and PC-3 membrane proteins were electrophoresed through a 10% SDS-PAGE resolving gel with a 4% stacking gel at 9-10 milliamps for 16-18 hours. Proteins were electroblotted onto PVDF membranes (Millipores Corp.) in transfer buffer (48 mM Tris base, 39 mM Glycine, 20% Methanol) at 25 volts overnight at 4° C.
- transfer buffer 48 mM Tris base, 39 mM Glycine, 20% Methanol
- Membranes were blocked in TSB (0.15M NaCl, 0.01M Tris base, 5% BSA) for 30 minutes at room temperature followed by incubation with 10-15 ⁇ g/ml of CYT-356 monoclonal antibody (Cytogen Corp.) for 2 hours. Membranes were then incubated with 10-15 ⁇ g/ml of rabbit anti-mouse immunoglobulin (Accurate Scientific) for 1 hour at room temperature followed by incubation with 125 I-Protein A (Amersham®) at 1 ⁇ 10 6 cpm/ml at room temperature. Membranes were then washed and autoradiographed for 12-24 hours at ⁇ 70° C. ( FIG. 1 ).
- the avidin-biotin method of immunohistochemical detection was employed to analyze both human tissue sections and cell lines for PSM Antigen expression (22).
- Cryostat-cut prostate tissue sections (4-6 ⁇ m thick) were fixed in methanol/acetone for 10 minutes.
- Cell cytospins were made on glass slides using 50,000 cells/100 ⁇ l/slide.
- Samples were treated with 1% hydrogen peroxide in PBS for 10-15 minutes in order to remove any endogenous peroxidase activity.
- Tissue sections were washed several times in PBS, and then incubated with the appropriate suppressor serum for 20 minutes. The suppressor serum was drained off and the sections or cells were then incubated with the diluted CYT-356 monoclonal antibody for 1 hour.
- 80%-confluent LNCaP cells in 100 mm petri dishes were starved in RPMI media without methionine for 2 hours, after which 35 S-Methionine was added at 100 ⁇ Ci/ml and the cells were grown for another 16-18 hours.
- Cells were then washed and lysed by the addition of 1 ml of lysis buffer (1% Triton X-100, 50 mM Hepes pH 7.5, 10% glycerol, 150 mM MgCl 2 , 1 mM PMSF, and 1 mM EGTA) with incubation for 20 minutes at 4° C. Lysates were pre-cleared by mixing with Pansorbin® cells (Calbiochem®) for 90 minutes at 4° C.
- lysis buffer 1% Triton X-100, 50 mM Hepes pH 7.5, 10% glycerol, 150 mM MgCl 2 , 1 mM PMSF, and 1 mM EGTA
- Cell lysates were then mixed with Protein A Sepharose® CL-4B beads (Pharmacia®) previously bound with CYT-356 antibody (Cytogen Corp.) and RAM antibody (Accurate Scientific) for 3-4 hours at 4° C. 12 ⁇ g of antibody was used per 3 mg of beads per petri dish. Beads were then washed with HNTG buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol, and 2 mM Sodium Orthovanadate), resuspended in sample loading buffer containing ⁇ -mercaptoethanol, denatured at 95° C.
- HNTG buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol, and 2 mM Sodium Orthovanadate
- the procedure described above for immunoprecipitation was repeated with 8 confluent petri dishes containing approximately 6 ⁇ 10 7 LNCaP cells.
- the immunoprecipitation product was pooled and loaded into two lanes of a 10% SDS-PAGE gel and electrophoresed at 9-10 milliamps for 16 hours. Proteins were electroblotted onto Nitrocellulose BA-85 membranes (Schleicher and Schuell®) for 2 hours at 75 volts at 4° C. in transfer buffer. Membranes were stained with Ponceau Red to visualize the proteins and the 100 kD protein band was excised, solubilized, and digested proteolytically with trypsin.
- PSM Antigen Peptide Sequences 2T17 #5 SLYES(W)TK (SEQ ID No. 3) 2T22 #9 (S)YPDGXNLPGG(g)VQR (SEQ ID No. 4) 2T26 #3 FYDPMFK (SEQ ID No. 5) 2T27 #4 IYNVIGTL(K) (SEQ ID No. 6) 2T34 #6 FLYXXTQIPHLAGTEQNFQLAK (SEQ ID No. 7) 2T35 #2 G/PVILYSDPADYFAPD/GVK (SEQ ID No. 8, 9) 2T38 #1 AFIDPLGLPDRPFYR (SEQ ID No.
- X means that no residue could be identified at this position.
- Capital denotes identification but with a lower degree of confidence. (lower case) means residue present but at very low levels . . . indicates sequence continues but has dropped below detection limit.
- Sense and anti-sense 5′-unphosphorylated degenerate oligonucleotide primers 17 to 20 nucleotides in length corresponding to portions of the above peptides were synthesized on an Applied Biosystems Model 394A DNA Synthesizer. These primers have degeneracies from 32 to 144. The primers used are shown below. The underlined amino acids in the peptides represent the residues used in primer design.
- Peptide 3 FYDPMF K (SEQ ID No. 5) PSM Primer “A” TT(C or T) - TA(C or T) - GA (SEQ ID No. 13) (C or T) - CCX - ATG - TT PSM Primer “B” AAC - ATX - GG(A or G) - TC (SEQ ID No. 14) (A or G) - TA(A or G) - AA
- Primer A is sense primer and B is anti-sense. Degeneracy is 32-fold.
- Peptide 4 IYNVIG TL(K) (SEQ ID No. 6) PSM Primer “C” AT(T or C or A) - TA(T or C) - AA (SEQ ID No. 15) (T or C) - GTX - AT(T or C or A) - GG PSM Primer “D” CC(A or T or G) - ATX - AC(G or (SEQ ID No. 16) A) - TT(A or G) - TA(A or G or T) - AT
- Primer C is sense-primer and D is anti-sense. Degeneracy is 144-fold.
- Peptide 2 ⁇ /PVILYSD PADYFA PD/GVK (SEQ ID No. 8, 9) PSM Primer “E” CCX - GCX - GA(T or C) - TA(T or (SEQ ID No. 17) C) - TT(T or C) - GC PSM Primer “F” GC(G or A) - AA(A or G) - TA(A or (SEQ ID No. 18) G) - TXC - GCX - GG
- Primer E is sense primer and F is antisense primer. Degeneracy is 128-fold.
- Peptide 6 FLYXXTQIPBLAG TEONFO LAK (SEQ ID No. 7) PSM Primer “I” ACX - GA(A or G) - CA(A or G) - AA (SEQ ID No. 19) (T or C) - TT(T or C) - CA(A or G) - CT PSM Primer “J” AG - (T or C)TG - (A or G)AA - (A (SEQ ID No. 20) or G)TT - (T or C)TG - (T or C) TC - XGT PSM Primer “K” GA(A or G) - CA(A or G) - AA(T or (SEQ ID No.
- Peptide 7 TILFAS (W)DAEEFG XX(q)STE(e)A(E) . . . (SEQ ID No. 12) PSM Primer “M” TGG - GA(T or C) - GCX - GA(A or (SEQ ID No. 23) G) - GA(A or G) - TT(C or T) - GG PSM Primer “N” CC - (G or A)AA - (T or C)TC - (T (SEQ ID No.
- Primers M and O are sense primers and N and P are anti-sense.
- M and N have degeneracy of 64-fold and O and P are 32-fold degenerate.
- cDNA template for the PCR was prepared from LNCaP mRNA which had been isolated by standard methods of oligo dT chromatography (Collaborative Research). The cDNA synthesis was carried out as follows: 4.5 ⁇ l LNCaP poly A+ RNA (2 ⁇ g) 1.0 ⁇ l Oligo dT primers (0.5 ⁇ g) 4.5 ⁇ l dH 2 O 10 ⁇ l
- PCR reactions were optimized by varying the annealing temperatures, Mg++ concentrations, primer concentrations, buffer composition, extension times and number of cycles.
- Our optimal thermal cycler profile was: Denaturation at 94° C. ⁇ 30 seconds, Annealing at 45-55° C. for 1 minute (depending on the mean T m of the primers used), and Extension at 72° C. for 2 minutes.
- Tubes were overlaid with 60 ⁇ l of light mineral oil and amplified for 30 cycles. PCR products were analyzed by electrophoresing 5 ⁇ l of each sample on a 2-3% agarose gel followed by staining with Ethidium bromide and photography.
- FIG. 5 Representative photographs displaying PCR products are shown in FIG. 5 .
- TA Cloning Invitrogen® Corp.
- the cloning strategy employed here is to directly ligate PCR products into a plasmid vector possessing overhanging T residues at the insertion site, exploiting the fact that Taq polymerase leaves overhanging A residues at the ends of the PCR products.
- the ligation mixes are transformed into competent E. coli cells and resulting colonies are grown up, plasmid DNA is isolated by the alkaline lysis method (24), and screened by restriction analysis ( FIG. 6 ).
- TA Clones of PCR products were then sequenced by the dideoxy method (25) using Sequenase (U.S. Biochemical). 3-4 ⁇ g of each plasmid DNA was denatured with NaOH and ethanol precipitated. Labeling reactions were carried out as per the manufacturers recommendations using 35 S-ATP, and the reactions were terminated as per the same protocol. Sequencing products were then analyzed on 6% polyacrylamide/7M Urea gels using an IBI sequencing apparatus. Gels were run at 120 watts for 2 hours. Following electrophoresis, the gels were fixed for 15-20 minutes in 10% methanol/10% acetic acid, transferred onto Whatman 3MM paper and dried down in a Biorad® vacuum dryer at 80° C. for 2 hours.
- underlined amino acids were the portion of peptide 6 that was used to design this sense primer and the remaining amino acids which agree with those present within our peptide confirm that this end of the molecule represents the correct protein (PSM antigen).
- underlined amino acids here represent the portion of peptide 7 used to create primer N. All of the amino acids upstream of this primer are correct in the IN-20 clone, agreeing with the amino acids found in peptide 7. Further DNA sequencing has enabled us to identify the presence of our other PSM peptides within the DNA sequence of our positive clone.
- a cDNA library from LNCaP mRNA was constructed using the Superscripts plasmid system (BRL®-Gibco). The library was transformed using competent DH5- ⁇ cells and plated onto 100 mm plates containing LB plus 100 ⁇ g/ml of Carbenicillin. Plates were grown overnight at 37° C. and colonies were transferred to nitrocellulose filters. Filters were processed and screened as per Grunstein and Hogness (26), using our 1.1 kb partial cDNA homologous probe which was radiolabelled with 32 P-dCTP by random priming (27). We obtained eight positive colonies which upon DNA restriction and sequencing analysis proved to represent full-length cDNA molecules coding for the PSM antigen. Shown in FIG.
- FIG. 7 is an autoradiogram showing the size of the cDNA molecules represented in our library and in FIG. 8 restriction analysis of several full-length clones is shown.
- FIG. 9 is a plasmid Southern analysis of the samples in FIG. 8 , showing that they all hybridize to the 1.1 kb partial cDNA probe.
- RNA samples (either 10 ⁇ g of total RNA or 2 ⁇ g of poly A+ RNA) were denatured and electrophoresed through 1.1% agarose/formaldehyde gels at 60 milliamps for 6-8 hours. RNA was then transferred to Nytran® nylon membranes (Schleicher and Schuell®) by pressure blotting in 10 ⁇ SSC with a Posi-blotter (Stratagene®). RNA was cross-linked to the membranes using a Stratalinker (Stratagene®) and subsequently baked in a vacuum oven at 80° C. for 2 hours. Blots were pre-hybridized at 65° C.
- PCR was performed on 15 human prostate samples to determine PSM gene expression. Five samples each from normal prostate tissue, benign prostatic hyperplasia, and prostate cancer were used (histology confirmed by MSKCC Pathology Department).
- RNA from each sample was reverse transcribed to made cDNA template as previously described in section IV.
- the primers used corresponded to the 5′ and 3′ ends of our 1.1 kb partial cDNA, IN-20, and therefore the expected size of the amplified band is 1.1 kb. Since the T m of our primers is 64° C. we annealed the primers in our PCR at 60° C. We carried out the PCR for 35 cycles using the same conditions previously described in section IV.
- LNCaP and H26—Ras transfected LNCaP (29) were included as a positive control and DU-145 as a negative control. 14/15 samples clearly amplified the 1.1 kb band and therefore express the gene.
- the gene which encodes the 100 kD PSM antigen has been identified.
- the complete cDNA sequence is shown in Sequence ID #1. Underneath that nucleic acid sequence is the predicted translated amino acid sequence. The total number of the amino acids is 750, ID 2.
- the hydrophilicity of the predicted protein sequence is shown in FIG. 15A . Shown in FIG. 15B are three peptides with the highest point of hydrophilicity. They are: Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 35); Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 36; and Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 37).
- This predicted membrane-spanning domain was computed on PC Gene (computer software program). This data enables prediction of inner and outer membrane domains of the PSM antigen which aids in designing antibodies for uses in targeting and imaging prostate cancer.
- Unambiguous tumor designation can be accomplished by use of probes for different antigens.
- the PSM antigen probe may prove beneficial.
- PSM could be used for diagnostic purposes and this could be accomplished at the microscopic level using in-situ hybridization using sense (control) and antisense probes derived from the coding region of the cDNA cloned by the applicants. This could be used in assessment of local extraprostatic extension, involvement of lymph node, bone or other metastatic sites.
- As bone metastasis presents a major problem in prostatic cancer early detection of metastatic spread is required especially for staging. In some tumors detection of tumor cells in bone marrow portends a grim prognosis and suggests that interventions aimed at metastasis be tried. Detection of PSM antigen expression in bone marrow aspirates or sections may provide such early information. PCR amplification or in-situ hybridization may be used. This could be developed for any possible metastatic region.
- the knowledge of the cDNA for the antigen also provides for the identification of areas that would serve as good antigens for the development of antibodies for use against specific amino acid sequences of the antigen. Such sequences may be at different regions such as outside, membrane or inside of the PSM antigen.
- the development of these specific antibodies would provide for immunohistochemical identification of the antigen.
- These derived antibodies could then be developed for use, especially ones that work in paraffin fixed sections as well as frozen section as they have the greatest utility for immunodiagnosis.
- Restriction fragment length polymorphisms have proven to be useful in documenting the progression of genetic damage that occurs during tumor initiation and promotion. It may be that RFLP analysis will demonstrate that changes in PSM sequence restriction mapping may provide evidence of predisposition to risk or malignant potential or progression of the prostatic tumor.
- the PSM antigen gene may serve as a useful chromosome location marker for chromosome analysis.
- antigen specific antibodies if the antigen or selected antigen fragments appear in the serum they may provide for a serum marker for the presence of metastatic disease and be useful individually or in combination with other prostate specific markers.
- the antigen has the characteristics of a membrane spanning protein with the majority of the protein on the exofacial surface
- antibodies especially monoclonal antibodies to the peptide fragments exposed and specific to the tumor may provide for tumor imaging local extension of metastatic tumor or residual tumor following prostatectomy or irradiation.
- the knowledge of the coding region permits the generation of monoclonal antibodies and these can be used in combination to provide for maximal imaging purposes.
- the antigen shares a similarity with the transferrin receptor based on cDNA analysis (approximately 54%), it may be that there is a specific normal ligand for this antigen and that identification of the ligand(s) would provide another means of imaging.
- the PSM antigen can be used to isolate the normal ligand(s) that bind to it. These ligand(s) depending on specificity may be used for targeting, or their serum levels may be predictive of disease status. If it is found that the normal ligand for PSM is a carrier molecule then it may be that PSM could be used to bind to that ligand for therapy purposes (like an iron chelating substance) to help remove the ligand from the circulation. If the ligand promotes tumor growth or metastasis then providing soluble PSM antigen would remove the ligand from binding the prostate. Knowledge of PSM antigen structure could lend to generation of small fragment that binds ligand which could serve the same purpose.
- a ligand may carry a specific substance such as a metal ion (iron or zinc or other) into the tumor and thus serve as a means to deliver toxic substances (radioactive or cytotoxic chemical i.e. toxin like ricin or cytotoxic alkylating agent or cytotoxic prodrug) to the tumor.
- a metal ion iron or zinc or other
- toxic substances radioactive or cytotoxic chemical i.e. toxin like ricin or cytotoxic alkylating agent or cytotoxic prodrug
- the main metastatic site for prostatic tumor is the bone.
- the bone and bone stroma are rich in transferrin. Recent studies suggest that this microenvironment is what provides the right “soil” for prostatic metastasis in the bone (31). It may be that this also promotes attachment as well, these factors which reduce this ability may diminish prostatic metastasis to the bone and prostatic metastatic growth in the bone.
- the ligand for the neu antigen (thought to be an oncogene and marker of malignant phenotype in breast carcinoma) served to induce differentiation of breast cancer cells and thus could serve as a treatment for rather than promotor of the disease. It may be that ligand binding to the right region of PSM whether with natural ligand or with an antibody may serve a similar function.
- Transferrin receptor antibodies with toxin conjugates are cytotoxic to a number of tumor cells as tumor cells tend to express increased levels of transferrin receptor (32). Transferrin receptors take up molecules into the cell by endocytosis. Antibody drug combinations can be toxic. Transferrin linked toxin can be toxic.
- the cytotoxic agent may be a radioisotope or toxin as known in ordinary skill of the art.
- the linkage of the antibody and the toxin or radioisotope can be chemical. Examples of direct linked toxins are doxorubicin, chlorambucil, ricin, pseudomonas exotoxin etc., or a hybrid toxin can be generated 1 ⁇ 2 with specificity for PSM and the other 1 ⁇ 2 with specificity for the toxin.
- Such a bivalent molecule can serve to bind to the tumor and the other 1 ⁇ 2 to deliver a cytotoxic to the tumor or to bind to and activate a cytotoxic lymphocyte such as binding to the T 1 -T 3 receptor complex.
- Antibodies of required specificity can also be cloned into T cells and by replacing the immunoglobulin domain of the T cell receptor (TcR); cloning in the desired MAb heavy and light chains; splicing the U h and U L gene segments with the constant regions of the ⁇ and ⁇ TCR chains and transfecting these chimeric Ab/TcR genes in the patients' T cells, propagating these hybrid cells and infusing them into the patient (33).
- tissue specific antigens for targets and generation of MAb's specific for such targets will help make this a usable approach.
- PSM antigen coding region provides knowledge of the entire coding region, it is possible to generate a number of antibodies which could then be used in combination to achieve an additive or synergistic anti-tumor action.
- the antibodies can be linked to enzymes which can activate non-toxic prodrugs at its site of the tumor such as Ab-carboxypeptidase and 4-(bis(2 chloroethyl)amino)benzoyl- ⁇ -glutamic acid and its active parent drug in mice (34).
- a toxic genetic chimera such as TP-40 a genetic recombinant that possesses the cDNA from TGF-alpha and the toxic portion of pseudomonas exotoxin so the TGF and portion of the hybrid binds the epidermal growth factor receptor (EGFR) and the pseudomonas portion gets taken up into the cell enzymatically and inactivates the ribosomes ability to perform protein synthesis resulting in cell death.
- EGFR epidermal growth factor receptor
- toxin can be chemically conjugated to the ligands.
- conjugated ligands can be therapeutically useful.
- the toxins are daunomycin, chlorambucil, ricin, pseudomonas exotoxin, etc.
- chimeric construct can be created linking the cDNA of the ligand with the cDNA of the toxin.
- the PSM antigen may have other uses. It is well known that the prostate is rich in zinc, if the antigen provides function relative to this or other biologic function the PSM antigen may provide for utility in the treatment of other prostatic pathologies such as benign hyperplastic growth and/or prostatitis.
- the purified PSM antigen can be linked to beads and use it like a standard “affinity” purification.
- Serum, urine or other biological samples can be used to incubate with the PSM antigen bound onto beads.
- the beads may be washed thoroughly and then eluted with salt or pH gradient.
- the eluted material is SDS gel purified and used as a sample for microsequencing.
- the sequences will be compared with other known proteins and if unique, the technique of degenerated PCR can be employed for obtaining the ligand. Once known, the affinity of the ligand will be determined by standard protocols (15).
Abstract
This invention provides an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention also provides prostate-specific membrane nucleic acid of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention further provides vector and vector host expression system for the prostate-specific membrane antigen. This invention also provides methods to identify ligands which bind to the prostate-specific membrane antigen, to generate antibody against a complete prostate-specific membrane antigen or a portion of the antigen. This invention further provides purified prostate-specific membrane antigen. This invention provides a therapeutic agent comprising an antibody directed against to prostate-specific membrane antigen and a cytotoxic agent conjugated thereto. This invention also provides a method of imaging prostate cancer and an immunoassay for measuring the amount of the prostate-specific membrane antigen in a biological simple. This invention further provides transgenic nonhuman mammal which comprises the isolated nucleic acid molecule encoding a mammalian prostate-specific membrane antigen.
Description
- Throughout this application various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the sequence listing and the claims.
- The prostate gland is a site of significant pathology affected by conditions such as benign growth (BPH) neoplasia (prostatic cancer) and infection (prostatitis). Prostate cancer represents the second leading cause of death from cancer in man (1). However prostatic cancer is the leading site for cancer development in men. The difference between these two facts relates to prostatic cancer occurring with increasing frequency as men age, especially in the ages beyond 60 at a time when death from other factors often intervenes. Also, the spectrum of biologic aggressiveness of prostatic cancer is great, so that in some men following detection the tumor remains a latent histologic tumor and does not become clinically significant, whereas in other it progresses rapidly, metastasizes and kills the man in a relatively short 2-5 year period (1, 2).
- In prostate cancer cells, two specific proteins that are made in very high concentrations are prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) (3, 4, 5). These proteins have been characterized and have been used to follow response to therapy. With the development of cancer, the normal architecture of the gland becomes altered, including loss of the normal duct structure for the removal of secretions and thus the secretions reach the serum. Indeed measurement of serum PSA is suggested as a potential screening method for prostatic cancer. Indeed, the relative amount of PSA and/or PAP in the cancer reduces as compared to normal or benign tissue.
- PAP was one of the earliest serum markers for detecting metastatic spread (3). PAP hydrolyses tyrosine phosphate and has a broad substrate specificity. Tyrosine phosphorylation is often increased with oncogenic transformation. It has been hypothesized that during neoplastic transformation there is less phosphatase activity available to inactivate proteins that are activated by phosphorylation on tyrosine residues. In some instances, insertion of phosphatases that have tyrosine phosphatase activity has reversed the malignant phenotype.
- PSA is a protease and it is not readily appreciated how loss of its activity correlates with cancer development (4, 5). The proteolytic activity of PSA is inhibited by zinc. Zinc concentrations are high in the normal prostate and reduced in prostatic cancer. Possibly the loss of zinc allows for increased proteolytic activity by PSA. As proteases are involved in metastasis and some proteases stimulate mitotic activity, the potentially increased activity of PSA could be hypothesized to play a role in the tumors metastases and spread (6).
- Both PSA and PAP are found in prostatic secretions. Both appear to be dependent on the presence of androgens for their production and are substantially reduced following androgen deprivation.
- Prostate-specific membrane antigen (PSM) which appears to be localized to the prostatic membrane has been identified. This antigen was identified as the result of generating monoclonal antibodies to a prostatic cancer cell, LNCaP (7).
- Dr. Horoszewicz established a cell line designated LNCaP from the lymph node of a hormone refractory, heavily pretreated patient (8). This line was found to have an aneuploid human male karyotype. It maintained prostatic differentiation functionality in that it produced both PSA and PAP. It possessed an androgen receptor of high affinity and specificity. Mice were immunized with LNCaP cells and hybridomas were derived from sensitized animals. A monoclonal antibody was derived and was designated 7E11-C5 (7). The antibody staining was consistent with a membrane location and isolated fractions of LNCaP cell membranes exhibited a strongly positive reaction with immunoblotting and ELISA techniques. This antibody did not inhibit or enhance the growth of LNCaP cells in vitro or in vivo. The antibody to this antigen was remarkably specific to prostatic epithelial cells, as no reactivity was observed in any other component. Immunohistochemical staining of cancerous epithelial cells was more intense than that of normal or benign epithelial cells.
- Dr. Horoszewicz also reported detection of immunoreactive material using 7E11-C5 in serum of prostatic cancer patients (7). The immunoreactivity was detectable in nearly 60% of patients with stage D-2 disease and in a slightly lower percentage of patients with earlier stage disease, but the numbers of patients in the latter group are small. Patients with benign prostatic hyperplasia (BPH) were negative. Patients with no apparent disease were negative, but 50-60% of patients in remission yet with active stable disease or with progression demonstrated positive serum reactivity. Patients with non prostatic tumors did not show immunoreactivity with 7E11-C5.
- The 7E11-C5 monoclonal antibody is currently in clinical trials. The aldehyde groups of the antibody were oxidized and the linker-chelator glycol-tyrosyl-(n, ε-diethylenetriamine-pentacetic acid)-lysine (GYK-DTPA) was coupled to the reactive aldehydes of the heavy chain (9). The resulting antibody was designated CYT-356. Immunohistochemical staining patterns were similar except that the CYT-356 modified antibody stained skeletal muscle. The comparison of CYT-356 with 7E11-C5 monoclonal antibody suggested both had binding to
type 2 muscle fibers. The reason for the discrepancy with the earlier study, which reported skeletal muscle to be negative, was suggested to be due to differences in tissue fixation techniques. Still, the most intense and definite reaction was observed with prostatic epithelial cells, especially cancerous cells. Reactivity with mouse skeletal muscle was detected with immunohistochemistry but not in imaging studies. The Indium111-labeled antibody localized to LNCaP tumors grown in nude mice with an uptake of nearly 30% of the injected dose per gram tumor at four days. In-vivo, no selective retention of the antibody was observed in antigen negative tumors such as PC-3 and DU-145, or by skeletal muscle. - Very little was known about the PSM antigen. An effort at purification and characterization has been described at meetings by Dr. George Wright and colleagues (10, 11). These investigators have shown that following electrophoresis on acrylamide gels and Western blotting, the PSM antigen appears to have a molecular weight of 100 kilodaltons (kd). Chemical and enzymatic treatment showed that both the peptide and carbohydrate moieties of the PSM antigen-are-required for recognition by the 7E11-C5 monoclonal antibody. Competitive binding studies with specific lectins suggested that galNAc is the dominant carbohydrate of the antigenic epitope.
- A 100 kd glycoprotein unique to prostate cells and tissues was purified and characterized. The protein was digested proteolytically with trypsin and nine peptide fragments were sequenced. Using the technique of degenerate PCR (polymerase chain reaction), the full-length 2.65 kilobase (kb) cDNA coding for this antigen was cloned. Preliminary results have revealed that this antigen is highly expressed in prostate cancer tissues, including bone and lymph node metastases (12). The entire DNA sequence for the cDNA as well as the predicted amino acid sequence for the antigen was determined. Further characterization of the PSM antigen is presently underway in the applicants' laboratory including: analysis of PSM gene expression in a wide variety of tissues, transfection of the PSM gene into cells not expressing the antigen, chromosome localization of the PSM gene, cloning of the genomic PSM gene with analysis of the PSM promoter and generation of polyclonal and monoclonal antibodies against highly antigenic peptide domains of the PSM antigen, and identification of any endogenous PSM binding molecules (ligands).
-
FIG. 1 Signal inlane 2 represent the 100 kD PSM antigen. The EGFr was used as the positive control and is shown inlane 1. Incubation with rabbit antimouse (RAM) antibody alone served as negative control and is shown inlane 3. -
FIG. 2 Upper two photos show LNCaP cytospins staining positively for PSM antigen. Lower left in DU-145 and lower right is PC-3 cytospin, both negative for PSM antigen expression. -
FIG. 3 Upper two panels are human prostate sections (BPH) staining positively for PSM antigen. The lower two panels show invasive prostate carcinoma human sections staining positively for expression of the PSM antigen. -
FIG. 4 100 kD PSM antigen following immunoprecipitation of 35S-Methionine labelled LNCaP cells with Cyt-356 antibody. -
FIG. 5 3% agarose gels stained with Ethidium bromide revealing PCR products obtained using the degenerate PSM antigen primers. The arrow points to sample IN-20, which is a 1.1 kb PCR product which we later confirmed to be a partial cDNA coding for the PSM gene. -
FIG. 6 2% agarose gels of plasmid DNA resulting from TA cloning of PCR products. Inserts are excised from the PCR II vector (Invitrogen Corp.) by digestion with EcoRI. 1.1 kb PSM gene partial cDNA product is shown inlane 3 ofgel 1. -
FIG. 7 Autoradiogram showing size of cDNA represented in applicants' LNCaP library. -
FIG. 8 Restriction analysis of full-length clones of PSM gene obtained after screening cDNA library. Samples have been cut with Not I and Sal I restriction enzymes to liberate the insert. -
FIG. 9 Plasmid Southern autoradiogram of full length PSM gene clones. Size is approximately 2.7 kb. -
FIG. 10 Northern blot revealing PSM expression limited to LNCaP prostate cancer line and H26 Ras-transfected LNCaP cell line. PC-3, DU-145, T-24, SKRC-27, HELA, MCF-7, HL-60, and others were are all negative. -
FIG. 11 Autoradiogram of Northern analysis revealing expression of 2.8 kb PSM message unique to the LNCaP cell line (lane 1), and absent from the DU-145 (lane 2) and PC-3 cell lines (lane 3). RNA size ladder is shown on the left (kb), and 28S and 18S ribosomal RNA bands are indicated on the right. -
FIG. 12 Results of PCR of human prostate tissues using PSM gene primers. Lanes are numbered from left to right.Lane 1, LNCaP;Lane 2, H26;Lane 3, DU-145; Lane 4, Normal Prostate;Lane 5, BPH;Lane 6, Prostate Cancer; Lane 7, BPH;Lane 8, Normal; Lane 9, BPH;Lane 10, BPH; Lane 11, BPH;Lane 12, Normal; Lane 13, Normal;Lane 14, Cancer; Lane 15, Cancer;Lane 16, Cancer; Lane 17, Normal;Lane 18, Cancer; Lane 19, IN-20 Control;Lane 20, PSM cDNA -
FIG. 13 Isoelectric point of PSM antigen (non-glycosylated) -
FIG. 14 Secondary structure of PSM antigen -
FIG. 15 A . Hydrophilicity plot of PSM antigen B. Prediction of membrane spanning segments -
FIG. 16 Homology with chicken, rat and human transferrin receptor sequence - This invention provides an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane (PSM) antigen. The isolated mammalian nucleic acid may be DNA, cDNA or RNA.
- This invention also provides nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding the PSM antigen. The nucleic acid molecule may either be DNA or RNA.
- This invention provides nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule which is complementary to the nucleic acid molecule encoding a mammalian prostate-specific membrane antigen.
- This invention further provides a method of detecting expression of the PSM antigen which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with a labelled PSM antigen specific nucleic acid molecule under hybridizing conditions, determining the presence of mRNA hybridized to the probe, and thereby detecting the expression of the PSM antigen by the cell. The PSM antigen in tissue sections may be similarly detected.
- This invention provides isolated nucleic acid sequence of PSM antigen operatively linked to a promoter of RNA transcription. This invention further provides a vector which comprises an isolated mammalian nucleic acid molecule of PSM antigen.
- This invention further provides a host vector system for the production of a polypeptide having the biological activity of a mammalian PSM antigen which comprises the vector comprising the mammalian nucleic acid molecule encoding a mammalian PSM antigen and a suitable host. The suitable host for the expression of PSM antigen may be a bacterial cell, insect cell, or mammalian cell.
- This invention also provides a method of producing a polypeptide having the biological activity of a mammalian PSM antigen which comprises growing the host cell of vector system having a vector comprising the isolated mammalian nucleic acid molecule encoding a mammalian PSM antigen and a suitable host under suitable conditions permitting production of the polypeptide and recovery of the polypeptide so produced.
- This invention provides a method for determining whether a ligand can bind to a mammalian PSM antigen which comprises contacting a mammalian cell having an isolated mammalian DNA molecule encoding a mammalian PSM antigen with the ligand under conditions permitting binding of ligands to the mammalian PSM antigen, and determining whether the ligand binds to a mammalian PSM antigen. This invention further provides ligands which bind to PSM antigen.
- This invention provides purified mammalian PSM antigen. This invention also provides a polypeptide encoded by the isolated mammalian nucleic acid molecule encoding a mammalian PSM antigen. This invention further provides a method to identify and purify ligands of mammalian PSM antigen.
- This invention further provides a method to produce both polyclonal and monoclonal antibody using purified PSM antigens or polypeptides encoded by an isolated mammalian nucleic acid molecule encoding a mammalian PSM antigen.
- This invention provides polyclonal and monoclonal antibody most likely but not limited to directed either to peptide Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 35), or Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 36) or Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 37) of the PSM antigen.
- This invention provides a therapeutic agent comprising an antibody directed against a mammalian PSM antigen and a cytotoxic agent conjugated thereto.
- This invention also provides a method of imaging prostate cancer in human patients which comprises administering to the patient at least one antibody directed against PSM antigen, capable of binding to the cell surface of the prostate cancer cell and labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface PSM antigen. This invention further provides a composition comprising an effective imaging amount of the antibody directed against PSM antigen and a pharmaceutically acceptable carrier.
- This invention further provides a method of imaging prostate cancer in human patients which comprises administering to the patient multiple antibodies directed towards different PSM epitopes.
- The invention also provides a method of imaging prostate cancer in human patients which comprises administering to the patient at least one ligand, capable of binding to the cell surface of the prostate cancer cell and labelled with an imaging agent under conditions so as to form a complex between the ligand and the cell surface PSM antigen. This invention further provides a composition comprising an effective imaging amount of PSM antigen and a pharmaceutically acceptable carrier.
- This invention provides an immunoassay for measuring the amount of the PSM antigen in a biological sample, e.g. serum, comprising steps of a) contacting the biological sample with at least one PSM antibody to form a complex with said antibody and the PSM antigen, and b) measuring the amount of PSM antigen in said biological sample by measuring the amount of said complex.
- This invention also provides an immunoassay for measuring the amount of the PSM antigen in a biological sample comprising steps of a) contacting the biological sample with at least one PSM ligand to form a complex with said ligand and the PSM antigen, and b) measuring the amount of the PSM antigen in said biological sample by measuring the amount of said complex.
- This invention provides a method to purify mammalian PSM antigen comprising steps of:
- a) coupling the antibody directed against PSM antigen to a solid matrix; b) incubating the coupled antibody of a) with a cell lysate containing PSM antigen under the condition permitting binding of the antibody and PSM antigen; c) washing the coupled solid matrix to eliminate impurities and d) eluting the PSM antigen from the bound antibody.
- This invention further provides transgenic nonhuman mammals which comprises an isolated nucleic acid molecule of PSM antigen. This invention also provides a transgenic nonhuman mammal whose genome comprises antisense DNA complementary to DNA encoding a mammalian PSM antigen so placed as to be transcribed into antisense mRNA complementary to mRNA encoding the PSM antigen and which hybridizes to mRNA encoding the PSM antigen thereby reducing its translation.
- Throughout this application, references to specific nucleotides are to nucleotides present on the coding strand of the nucleic acid. The following standard abbreviations are used throughout the specification to indicate specific nucleotides:
-
- C=cytosine A=adenosine
- T=thymidine G=guanosine
- This invention provides an isolated mammalian nucleic acid encoding a mammalian prostate-specific membrane (PSM) antigen.
- This invention further provides an isolated mammalian DNA molecule of an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention also provides an isolated mammalian cDNA molecule encoding a mammalian prostate-specific membrane antigen. This invention provides an isolated mammalian RNA molecule encoding a mammalina prostate-specific membrane antigen.
- In the preferred embodiment of this invention, the isolated nucleic sequence is cDNA from human as shown in
sequence ID number 1. This human sequence was submitted to GenBank (Los Alamos National Laboratory, Los Alamos, N. Mex.) with Accession Number, M99487 and the description as PSM, Homo sapiens, 2653 base-pairs. - This invention also encompasses DNAs and cDNAs which encode amino acid sequences which differ from those of PSM antigen, but which should not produce phenotypic changes. Alternatively, this invention also encompasses DNAs and cDNAs which hybridize to the DNA and cDNA of the subject invention. Hybridization methods are well known to those of skill in the art.
- The DNA molecules of the subject invention also include DNA molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms. These molecules include: the incorporation of codons “preferred” for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.
- The DNA molecules described and claimed herein are useful for the information which they provide concerning the amino acid sequence of the polypeptide and as products for the large scale synthesis of the polypeptide by a variety of recombinant techniques. The molecule is useful for generating new cloning and expression vectors, transformed and transfected prokaryotic and eukaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide and related products.
- Moreover, the isolated mammalian nucleic acid molecules encoding a mammalian prostate-specific membrane antigen are useful for the development of probes to study the tumorigenesis of prostate cancer.
- This invention also provides nucleic acid molecules of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule encoding the prostate-specific membrane antigen.
- This nucleic acid molecule produced can either be DNA or RNA. As used herein, the phrase “specifically hybridizing” means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its own and to form double-helical segments through hydrogen bonding between complementary base pairs.
- This nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule encoding the prostate-specific membrane antigen can be used as a probe. Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe. DNA probe molecules may be produced by insertion of a DNA molecule which encodes PSM antigen into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable bacterial host cells, replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers.
- RNA probes may be generated by inserting the PSM antigen molecule downstream of a bacteriophage promoter such as T3, T7 or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with the linearized PSM antigen fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase.
- This invention also provides a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule which is complementary to the mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This molecule may either be a DNA or RNA molecule.
- The current invention further provides a method of detecting the expression of a mammalian PSM antigen expression in a cell which comprises obtaining total mRNA from the cell, contacting the mRNA so obtained with a labelled nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of the nucleic acid molecule encoding a mammalian PSM antigen under hybridizing conditions, determining the presence of mRNA hybridized to the molecule and thereby detecting the expression of the mammalian prostate-specific membrane antigen in the cell. The nucleic acid molecules synthesized above may be used to detect expression of a PSM antigen by detecting the presence of mRNA coding for the PSM antigen. Total mRNA from the cell may be isolated by many procedures well known to a person of ordinary skill in the art. The hybridizing conditions of the labelled nucleic acid molecules may be determined by routine experimentation well known in the art. The presence of mRNA hybridized to the probe may be determined by gel electrophoresis or other methods known in the art. By measuring the amount of the hybrid made, the expression of the PSM antigen by the cell can be determined. The labelling may be radioactive. For an example, one or more radioactive nucleotides can be incorporated in the nucleic acid when it is made.
- In one embodiment of this invention, nucleic acids are extracted by precipitation from lysed cells and the mRNA is isolated from the extract using an oligo-dT column which binds the poly-A tails of the mRNA molecules (13). The mRNA is then exposed to radioactively labelled probe on a nitrocellulose membrane, and the probe hybridizes to and thereby labels complementary mRNA sequences. Binding may be detected by luminescence autoradiography or scintillation counting. However, other methods for performing these steps are well known to those skilled in the art, and the discussion above is merely an example.
- This invention further provides another method to detect expression of a PSM antigen in tissue sections which comprises contacting the tissue sections with a labelled nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of nucleic acid molecules encoding a mammalian PSM antigen under hybridizing conditions, determining the presence of mRNA hybridized to the molecule and thereby detecting the expression of the mammalian PSM antigen in tissue sections. The probes are also useful for in-situ hybridization or in order to locate tissues which express this gene, or for other hybridization assays for the presence of this gene or its mRNA in various biological tissues. The in-situ hybridization using a labelled nucleic acid molecule is well known in the art. Essentially, tissue sections are incubated with the labelled nucleic acid molecule to allow the hybridization to occur. The molecule will carry a marker for the detection because it is “labelled”, the amount of the hybrid will be determined based on the detection of the amount of the marker and so will the expression of PSM antigen.
- This invention further provides isolated PSM antigen nucleic acid molecule operatively linked to a promoter of RNA transcription. The isolated PSM antigen sequence can be linked to vector systems. Various vectors including plasmid vectors, cosmid vectors, bacteriophage vectors and other viruses are well known to ordinary skilled practitioners. This invention further provides a vector which comprises the isolated nucleic acid molecule encoding for the PSM antigen.
- As an example to obtain these vectors, insert and vector DNA can both be exposed to a restriction enzyme to create complementary ends on both molecules which base pair with each other and are then ligated together with DNA ligase. Alternatively, linkers can be ligated to the insert DNA which correspond to a restriction site in the vector DNA, which is then digested with the restriction enzyme which cuts at that site. Other means are also available and known to an ordinary skilled practitioner.
- In an embodiment, the PSM sequence is cloned in the Not I/Sal I site of pSPORT/vector (Gibco®-BRL). This plasmid, p55A-PSM, was deposited on Aug. 14, 1992 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. Plasmid, p55A-PSM, was accorded ATCC Accession Number 75294.
- This invention further provides a host vector system for the production of a polypeptide having the biological activity of the prostate-specific membrane antigen. These vectors may be transformed into a suitable host cell to form a host cell vector system for the production of a polypeptide having the biological activity of PSM antigen.
- Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG (14). Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art, for example the methods described above for constructing vectors in general. Expression vectors are useful to produce cells that express the PSM antigen.
- This invention further provides an isolated DNA or cDNA molecule described hereinabove wherein the host cell is selected from the group consisting of bacterial cells (such as E. coli), yeast cells, fungal cells, insect cells and animal cells. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CV1 cells and various primary mammalian cells.
- This invention further provides a method of producing a polypeptide having the biological activity of the prostate-specific membrane antigen which comprising growing host cells of a vector system containing the PSM antigen sequence under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.
- This invention provides a mammalian cell comprising a DNA molecule encoding a mammalian PSM antigen, such as a mammalian cell comprising a plasmid adapted for expression in a mammalian cell, which comprises a DNA molecule encoding a mammalian PSM antigen and the regulatory elements necessary for expression of the DNA in the mammalian cell so located relative to the DNA encoding the mammalian PSM antigen as to permit expression thereof.
- Numerous mammalian cells may be used as hosts, including, but not limited to, the mouse fibroblast cell NIH3T3, CHO cells, HeLa cells, Ltk− cells, Cos cells, etc. Expression plasmids such as that described supra may be used to transfect mammalian cells by methods well known in the art such as calcium phosphate precipitation, electroporation or DNA encoding the mammalian PSM antigen may be otherwise introduced into mammalian cells, e.g., by microinjection, to obtain mammalian cells which comprise DNA, e.g., cDNA or a plasmid, encoding a mammalian PSM antigen.
- This invention provides a method for determining whether a ligand can bind to a mammalian prostate-specific membrane antigen which comprises contacting a mammalian cell comprising an isolated DNA molecule encoding a mammalian prostate-specific membrane antigen with the ligand under conditions permitting binding of ligands to the mammalian prostate-specific membrane antigen, and thereby determining whether the ligand binds to a mammalian prostate-specific membrane antigen.
- This invention further provides ligands bound to the mammalian PSM antigen.
- This invention also provides a therapeutic agent comprising a ligand identified by the above-described method and a cytotoxic agent conjugated thereto. The cytotoxic agent may either be a radioisotope or a toxin. Examples of radioisotopes or toxins are well known to one of ordinary skill in the art.
- This invention also provides a method of imaging prostate cancer in human patients which comprises administering to the patients at least one ligand identified by the above-described method, capable of binding to the cell surface of the prostate cancer cell and labelled with an imaging agent under conditions permitting formation of a complex between the ligand and the cell surface PSM antigen. This invention further provides a composition comprising an effective imaging agent of the PSM antigen ligand and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to one of ordinary skill in the art. For an example, such a pharmaceutically acceptable carrier can be physiological saline.
- Also provided by this invention is a purified mammalian PSM antigen. As used herein, the term “purified prostate-specific membrane antigen” shall mean isolated naturally-occurring prostate-specific membrane antigen or protein (purified from nature or manufactured such that the primary, secondary and tertiary conformation, and posttranslational modifications are identical to naturally-occurring material) as well as non-naturally occurring polypeptides having a primary structural conformation (i.e. continuous sequence of amino acid residues). Such polypeptides include derivatives and analogs.
- This invention further provides a polypeptide encoded by the isolated mammalian nucleic acid sequence of PSM antigen.
- It is believed that there may be natural ligand interacting with the PSM antigen. This invention provides a method to identify such natural ligand or other ligand which can bind to the PSM antigen. A method to identify the ligand comprises a) coupling the purified mammalian PSM antigen to a solid matrix, b) incubating the coupled purified mammalian PSM protein with the potential ligands under the conditions permitting binding of ligands and the purified PSM antigen; c) washing the ligand and coupled purified mammalian PSM antigen complex formed in b) to eliminate the nonspecific binding and impurities and finally d) eluting the ligand from the bound purified mammalian PSM antigen. The techniques of coupling proteins to a solid matrix are well known in the art. Potential ligands may either be deduced from the structure of mammalian PSM or by other empirical experiments known by ordinary skilled practitioners. The conditions for binding may also easily be determined and protocols for carrying such experimentation have long been well documented (15). The ligand-PSM antigen complex will be washed. Finally, the bound ligand will be eluted and characterized. Standard ligands characterization techniques are well known in the art.
- The above method may also be used to purify ligands from any biological source. For purification of natural ligands in the cell, cell lysates, serum or other biological samples will be used to incubate with the mammalian PSM antigen bound on a matrix. Specific natural ligand will then be identified and purified as above described.
- With the protein sequence information, antigenic areas may be identified and antibodies directed against these areas may be generated and targeted to the prostate cancer for imaging the cancer or therapies.
- This invention provides an antibody directed against the amino acid sequence of a mammalian PSM antigen.
- This invention provides a method to select specific regions on the PSM antigen to generate antibodies. The protein sequence may be determined from the PSM DNA sequence. Amino acid sequences may be analyzed by methods well known to those skilled in the art to determine whether they produce hydrophobic or hydrophilic regions in the proteins which they build. In the case of cell membrane proteins, hydrophobic regions are well known to form the part of the protein that is inserted into the lipid bilayer of the cell membrane, while hydrophilic regions are located on the cell surface, in an aqueous environment. Usually, the hydrophilic regions will be more immunogenic than the hydrophobic regions. Therefore the hydrophilic amino acid sequences may be selected and used to generate antibodies specific to mammalian PSM antigen. For an example, hydrophilic sequences of the human PSM antigen shown in hydrophilicity plot of
FIG. 15A may be easily selected. The selected peptides may be prepared using commercially available machines. As an alternative, DNA, such as a cDNA or a fragment thereof, may be cloned and expressed and the resulting polypeptide recovered and used as an immunogen. - Polyclonal antibodies against these peptides may be produced by immunizing animals using the selected peptides. Monoclonal antibodies are prepared using hybridoma technology by fusing antibody producing B cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody. Alternatively, monoclonal antibodies may be produced by in vitro techniques known to a person of ordinary skill in the art. These antibodies are useful to detect the expression of mammalian PSM antigen in living animals, in humans, or in biological tissues or fluids isolated from animals or humans.
- In one embodiment, peptides Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 35), Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 36) and Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 37) of human PSM antigen are selected.
- This invention further provides polyclonal and monoclonal antibody(ies) against peptides Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 35), Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 36) and Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 37).
- This invention provides a therapeutic agent comprising antibodies or ligand(s) directed against PSM antigen and a cytotoxic agent conjugated thereto or antibodies linked enzymes which activate prodrug to kill the tumor. The cytotoxic agent may either be a radioisotope or toxin.
- This invention provides a method of imaging prostate cancer in human patients which comprises administering to the patient the monoclonal antibody directed against the peptide of the mammalian PSM antigen capable of binding to the cell surface of the prostate cancer cell and labeled with an imaging agent under conditions permitting formation of a complex between the monoclonal antibody and the cell surface prostate-specific membrane antigen. The imaging agent is a radioisotope such as Indium111.
- This invention further provides a prostate cancer specific imaging agent comprising the antibody directed against PSM antigen and a radioisotope conjugated thereto.
- This invention also provides a composition comprising an effective imaging amount of the antibody directed against the PSM antigen and a pharmaceutically acceptable carrier. The methods to determine effective imaging amounts are well known to a skilled practitioner. One method is by titration using different amounts of the antibody.
- This invention further provides an immunoassay for measuring the amount of the prostate-specific membrane antigen in a biological sample comprising steps of a) contacting the biological sample with at least one antibody directed against the PSM antigen to form a complex with said antibody and the prostate-specific membrane antigen, and b) measuring the amount of the prostate-specific membrane antigen in said biological sample by measuring the amount of said complex. One example of the biological sample is a serum sample.
- This invention provides a method to purify mammalian prostate-specific membrane antigen comprising steps of a) coupling the antibody directed against the PSM antigen to a solid matrix; b) incubating the coupled antibody of a) with lysate containing prostate-specific membrane antigen under the condition which the antibody and prostate membrane specific can bind; c) washing the solid matrix to eliminate impurities and d) eluting the prostate-specific membrane antigen from the coupled antibody.
- This invention also provides a transgenic nonhuman mammal which comprises the isolated nucleic acid molecule encoding a mammalian PSM antigen. This invention further provides a transgenic nonhuman mammal whose genome comprises antisense DNA complementary to DNA encoding a mammalian prostate-specific membrane antigen so placed as to be transcribed into antisense mRNA complementary to mRNA encoding the prostate-specific membrane antigen and which hybridizes to mRNA encoding the prostate specific antigen thereby reducing its translation.
- Animal model systems which elucidate the physiological and behavioral roles of mammalian PSM antigen are produced by creating transgenic animals in which the expression of the PSM antigen is either increased or decreased, or the amino acid sequence of the expressed PSM antigen is altered, by a variety of techniques. Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding a mammalian PSM antigen, by microinjection, electroporation, retroviral transfection or other means well known to those skilled in the art, into appropriate fertilized embryos in order to produce a transgenic animal (16) or 2) Homologous recombination (17) of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these PSM antigen sequences. The technique of homologous recombination is well known in the art. It replaces the native gene with the inserted gene and so is useful for producing an animal that cannot express native PSM antigen but does express, for example, an inserted mutant PSM antigen, which has replaced the native PSM antigen in the animal's genome by recombination, resulting in underexpression of the transporter. Microinjection adds genes to the genome, but does not remove them, and so is useful for producing an animal which expresses its own and added PSM antigens, resulting in overexpression of the PSM antigens.
- One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as M2 medium (16). DNA or cDNA encoding a mammalian PSM antigen is purified from a vector by methods well known in the art. Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the trans-gene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the trans-gene. The DNA, in an appropriately buffered solution, is put into a microinjection needle (which may be made from capillary tubing using a pipet puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse (a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant), where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the only method for inserting DNA into the egg cell, and is used here only for exemplary purposes.
- Another use of the PSM antigen sequence is to isolate homologous gene or genes in different mammals. The gene or genes can be isolated by low stringency screening of either cDNA or genomic libraries of different mammals using probes from PSM sequence. The positive clones identified will be further analyzed by DNA sequencing techniques which are well known to an ordinary person skilled in the art. For example, the detection of members of the protein serine kinase family by homology probing (18).
- This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
- Materials and Methods
- The approach for cloning the gene involved purification of the antigen in large quantities by immunoprecipitation, and microsequencing of several internal peptides for use in synthesizing degenerate oligonucleotide primers for subsequent use in the polymerase chain reaction (19, 20). A partial cDNA was amplified as a PCR product and this was used as a homologous probe to clone the full-length cDNA molecule from a LNCaP (Lymph Node Carcinoma of Prostate) cell line cDNA plasmid library (8). Early experiments revealed to us that the CYT-356 antibody (9) was not capable of detecting the antigen produced in bacteria since the epitope was the glycosylated portion of the PSM antigen, and this necessitated our more difficult, yet elaborate approach.
- I. Western Analysis of the PSM Antigen
- Membrane proteins were isolated from cells by hypotonic lysis followed by centrifugation over a sucrose density gradient (21). 10-20 μg of LNCaP, DU-145, and PC-3 membrane proteins were electrophoresed through a 10% SDS-PAGE resolving gel with a 4% stacking gel at 9-10 milliamps for 16-18 hours. Proteins were electroblotted onto PVDF membranes (Millipores Corp.) in transfer buffer (48 mM Tris base, 39 mM Glycine, 20% Methanol) at 25 volts overnight at 4° C. Membranes were blocked in TSB (0.15M NaCl, 0.01M Tris base, 5% BSA) for 30 minutes at room temperature followed by incubation with 10-15 μg/ml of CYT-356 monoclonal antibody (Cytogen Corp.) for 2 hours. Membranes were then incubated with 10-15 μg/ml of rabbit anti-mouse immunoglobulin (Accurate Scientific) for 1 hour at room temperature followed by incubation with 125I-Protein A (Amersham®) at 1×106 cpm/ml at room temperature. Membranes were then washed and autoradiographed for 12-24 hours at −70° C. (
FIG. 1 ). - II. Immunohistochemical Analysis of PSM Antigen Expression
- The avidin-biotin method of immunohistochemical detection was employed to analyze both human tissue sections and cell lines for PSM Antigen expression (22). Cryostat-cut prostate tissue sections (4-6 μm thick) were fixed in methanol/acetone for 10 minutes. Cell cytospins were made on glass slides using 50,000 cells/100 μl/slide. Samples were treated with 1% hydrogen peroxide in PBS for 10-15 minutes in order to remove any endogenous peroxidase activity. Tissue sections were washed several times in PBS, and then incubated with the appropriate suppressor serum for 20 minutes. The suppressor serum was drained off and the sections or cells were then incubated with the diluted CYT-356 monoclonal antibody for 1 hour. Samples were then washed with PBS and sequentially incubated with secondary antibodies (horse or goat immunoglobulins, 1:200 dilution for 30 minutes), and with avidin-biotin complexes (1:25 dilution for 30 minutes). DAB was used as a chromogen, followed by hematoxylin counterstaining and mounting. Frozen sections of prostate samples and duplicate cell cytospins were used as controls for each experiment. As a positive control, the anti-cytokeratin monoclonal antibody CAM 5.2 was used following the same procedure described above. Tissue sections are considered by us to express the PSM antigen if at least 5% of the cells demonstrate immunoreactivity. Our scoring system is as follows: 1=<5%; 2=5-19%; 3=20-75%; and 4=>75% positive cells. Homogeneity versus heterogeneity was accounted for by evaluating positive and negative cells in 3-5 high power light microscopic fields (400×), recording the percentage of positive cells among 100-500 cells. The intensity of immunostaining is graded on a 1+ to 4+ scale, where 1+ represents mild, 2-3+ represents moderate, and 4+ represents intense immunostaining as compared to positive controls.
- III. Immunoprecipitation of the PSM Antigen
- 80%-confluent LNCaP cells in 100 mm petri dishes were starved in RPMI media without methionine for 2 hours, after which 35S-Methionine was added at 100 μCi/ml and the cells were grown for another 16-18 hours. Cells were then washed and lysed by the addition of 1 ml of lysis buffer (1% Triton X-100, 50 mM Hepes pH 7.5, 10% glycerol, 150 mM MgCl2, 1 mM PMSF, and 1 mM EGTA) with incubation for 20 minutes at 4° C. Lysates were pre-cleared by mixing with Pansorbin® cells (Calbiochem®) for 90 minutes at 4° C. Cell lysates were then mixed with Protein A Sepharose® CL-4B beads (Pharmacia®) previously bound with CYT-356 antibody (Cytogen Corp.) and RAM antibody (Accurate Scientific) for 3-4 hours at 4° C. 12 μg of antibody was used per 3 mg of beads per petri dish. Beads were then washed with HNTG buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol, and 2 mM Sodium Orthovanadate), resuspended in sample loading buffer containing β-mercaptoethanol, denatured at 95° C. for 5-10 minutes and run on a 10% SDS-PAGE gel with a 4° stacking gel at 10 milliamps overnight. Gels were stained with Coomassie Blue, destained with acetic acid/methanol, and dried down in a vacuum dryer at 60° C. Gels were then autoradiographed for 16-24 hours at −70° C. (
FIG. 2 ). - IV. Large-Scale Immunoprecipitation and Peptide Sequencing
- The procedure described above for immunoprecipitation was repeated with 8 confluent petri dishes containing approximately 6×107 LNCaP cells. The immunoprecipitation product was pooled and loaded into two lanes of a 10% SDS-PAGE gel and electrophoresed at 9-10 milliamps for 16 hours. Proteins were electroblotted onto Nitrocellulose BA-85 membranes (Schleicher and Schuell®) for 2 hours at 75 volts at 4° C. in transfer buffer. Membranes were stained with Ponceau Red to visualize the proteins and the 100 kD protein band was excised, solubilized, and digested proteolytically with trypsin. HPLC was then performed on the digested sample on an Applied Biosystems Model 171C and clear dominant peptide peaks were selected and sequenced by modified Edman degradation on a modified post liquid Applied Biosystems Model 477A Protein/Peptide Microsequencer (23). Sequencing data on all of the peptides is included within this document. We attempted to sequence the amino-terminus of the PSM antigen by a similar method which involved purifying the antigen by immunoprecipitation and transfer via electro-blotting to a PVDF membrane (Millipore®). Protein was analyzed on an Applied Biosystems Model 477A Protein/Peptide Sequencer and the amino terminus was found to be blocked, and therefore no sequence data could be obtained by this technique.
- PSM Antigen Peptide Sequences:
2T17 # 5SLYES(W)TK (SEQ ID No. 3) 2T22 #9 (S)YPDGXNLPGG(g)VQR (SEQ ID No. 4) 2T26 # 3FYDPMFK (SEQ ID No. 5) 2T27 #4 IYNVIGTL(K) (SEQ ID No. 6) 2T34 # 6FLYXXTQIPHLAGTEQNFQLAK (SEQ ID No. 7) 2T35 #2 G/PVILYSDPADYFAPD/GVK (SEQ ID No. 8, 9) 2T38 # 1AFIDPLGLPDRPFYR (SEQ ID No. 10) 2T46 # 8YAGESFPGIYDALFDIESK (SEQ ID No. 11) 2T47 #7 TILFAS(W)DAEEFGXX(q)STE(e)A (SEQ ID No. 12) (E) . . . - Notes: X means that no residue could be identified at this position. Capital denotes identification but with a lower degree of confidence. (lower case) means residue present but at very low levels . . . indicates sequence continues but has dropped below detection limit.
- All of these peptide sequences were verified to be unique after a complete homology search of the translated Genbank computer database.
- IV. Degenerate PCR
- Sense and anti-sense 5′-unphosphorylated degenerate oligonucleotide primers 17 to 20 nucleotides in length corresponding to portions of the above peptides were synthesized on an Applied Biosystems Model 394A DNA Synthesizer. These primers have degeneracies from 32 to 144. The primers used are shown below. The underlined amino acids in the peptides represent the residues used in primer design.
- Peptide 3: FYDPMFK (SEQ ID No. 5)
PSM Primer “A” TT(C or T) - TA(C or T) - GA (SEQ ID No. 13) (C or T) - CCX - ATG - TT PSM Primer “B” AAC - ATX - GG(A or G) - TC (SEQ ID No. 14) (A or G) - TA(A or G) - AA - Primer A is sense primer and B is anti-sense. Degeneracy is 32-fold.
- Peptide 4: IYNVIGTL(K) (SEQ ID No. 6)
PSM Primer “C” AT(T or C or A) - TA(T or C) - AA (SEQ ID No. 15) (T or C) - GTX - AT(T or C or A) - GG PSM Primer “D” CC(A or T or G) - ATX - AC(G or (SEQ ID No. 16) A) - TT(A or G) - TA(A or G or T) - AT - Primer C is sense-primer and D is anti-sense. Degeneracy is 144-fold.
- Peptide 2: α/PVILYSDPADYFAPD/GVK (SEQ ID No. 8, 9)
PSM Primer “E” CCX - GCX - GA(T or C) - TA(T or (SEQ ID No. 17) C) - TT(T or C) - GC PSM Primer “F” GC(G or A) - AA(A or G) - TA(A or (SEQ ID No. 18) G) - TXC - GCX - GG - Primer E is sense primer and F is antisense primer. Degeneracy is 128-fold.
- Peptide 6: FLYXXTQIPBLAGTEONFOLAK (SEQ ID No. 7)
PSM Primer “I” ACX - GA(A or G) - CA(A or G) - AA (SEQ ID No. 19) (T or C) - TT(T or C) - CA(A or G) - CT PSM Primer “J” AG - (T or C)TG - (A or G)AA - (A (SEQ ID No. 20) or G)TT - (T or C)TG - (T or C) TC - XGT PSM Primer “K” GA(A or G) - CA(A or G) - AA(T or (SEQ ID No. 21) C) - TT(T or C) CA(A or G) - CT PSM Primer “L” AG - (T or C)TG - (A or G)AA - (A (SEQ ID No. 22) or G)TT - (T or C)TG - (T or C)TC
Primers I and K are sense primers and J and L are anti-sense. I and J have degeneracies of 128-fold and K and L have 32-fold degeneracy. - Peptide 7: TILFAS(W)DAEEFGXX(q)STE(e)A(E) . . . (SEQ ID No. 12)
PSM Primer “M” TGG - GA(T or C) - GCX - GA(A or (SEQ ID No. 23) G) - GA(A or G) - TT(C or T) - GG PSM Primer “N” CC - (G or A)AA - (T or C)TC - (T (SEQ ID No. 24) or C)TC - XGC - (A or G)TC - CCA PSM Primer “O” TGG - GA(T or C) - GCX - GA(A or (SEQ ID No. 25) G) - GA(A or G) - TT PSM Primer “P” AA - (T or C)TC - (T or C)TC - (SEQ ID No. 26) XGC - (A or G)TC - CCA - Primers M and O are sense primers and N and P are anti-sense. M and N have degeneracy of 64-fold and O and P are 32-fold degenerate.
- Degenerate PCR was performed using a Perkin-
Elmer Model 480 DNA thermal cycler. cDNA template for the PCR was prepared from LNCaP mRNA which had been isolated by standard methods of oligo dT chromatography (Collaborative Research). The cDNA synthesis was carried out as follows:4.5 μl LNCaP poly A+ RNA (2 μg) 1.0 μl Oligo dT primers (0.5 μg) 4.5 μl dH2O 10 μl - Incubate at 68° C.×10 minutes.
- Quick chill on ice×5 minutes.
- Add:
4 μl 5× RT Buffer 2 μl 0.1M DTT 1 μl 10 mM dNTPs 0.5 μl RNasin (Promega) 1.5 μl dH2O 19 μl - Incubate for 2 minutes at 37° C.
- Add 1 μg Superscript® Reverse Transcriptase (Gibco®-BRL)
- Incubate for 1 hour at 37° C.
- Add 30 μl dH2O.
-
Use 2 μl per PCR reaction. - Degenerate PCR reactions were optimized by varying the annealing temperatures, Mg++ concentrations, primer concentrations, buffer composition, extension times and number of cycles. Our optimal thermal cycler profile was: Denaturation at 94° C.×30 seconds, Annealing at 45-55° C. for 1 minute (depending on the mean Tm of the primers used), and Extension at 72° C. for 2 minutes.
5 μl 10× PCR Buffer* 5 μl 2.5 mM dNTP Mix 5 μl Primer Mix (containing 0.5-1.0 μg each of sense and anti-sense primers) 5 μl 100 mM β- mercaptoethanol 2 μl LNCaP cDNA template 5 μl 25 mM MgCl2 (2.5 mM final) 21 μl dH2O 2 μl diluted Taq Polymerase (0.5 U/μl) 50 μl total volume - Tubes were overlaid with 60 μl of light mineral oil and amplified for 30 cycles. PCR products were analyzed by electrophoresing 5 μl of each sample on a 2-3% agarose gel followed by staining with Ethidium bromide and photography.
- *10×PCR Buffer
-
- 166 mM NH4SO4
- 670 mM Tris, pH 8.8
- 2 mg/ml BSA
- Representative photographs displaying PCR products are shown in
FIG. 5 . - V. Cloning of PCR Products
- In order to further analyze these PCR products, these products were cloned into a suitable plasmid vector using “TA Cloning” (Invitrogen® Corp.). The cloning strategy employed here is to directly ligate PCR products into a plasmid vector possessing overhanging T residues at the insertion site, exploiting the fact that Taq polymerase leaves overhanging A residues at the ends of the PCR products. The ligation mixes are transformed into competent E. coli cells and resulting colonies are grown up, plasmid DNA is isolated by the alkaline lysis method (24), and screened by restriction analysis (
FIG. 6 ). - VI. DNA Sequencing of PCR Products
- TA Clones of PCR products were then sequenced by the dideoxy method (25) using Sequenase (U.S. Biochemical). 3-4 μg of each plasmid DNA was denatured with NaOH and ethanol precipitated. Labeling reactions were carried out as per the manufacturers recommendations using 35S-ATP, and the reactions were terminated as per the same protocol. Sequencing products were then analyzed on 6% polyacrylamide/7M Urea gels using an IBI sequencing apparatus. Gels were run at 120 watts for 2 hours. Following electrophoresis, the gels were fixed for 15-20 minutes in 10% methanol/10% acetic acid, transferred onto Whatman 3MM paper and dried down in a Biorad® vacuum dryer at 80° C. for 2 hours. Gels were then autoradiographed at room temperature for 16-24 hours. In order to determine whether the PCR products were the correct clones, we analyzed the sequences obtained at the 5′ and 3′ ends of the molecules looking for the correct primer sequences, as well as adjacent sequences which corresponded to portions of the peptides not used in the design of the primers.
- IN-20 was confirmed to be correct and represent a partial cDNA for the PSM gene. In this PCR reaction, I and N primers were used. The DNA sequence we obtained when reading from the I primer was:
ACG GAG CAA AAC TTT CAG CTT GCA (SEQ ID No. 30) AAG T E Q N F Q L A (SEQ ID No. 31) K - The underlined amino acids were the portion of
peptide 6 that was used to design this sense primer and the remaining amino acids which agree with those present within our peptide confirm that this end of the molecule represents the correct protein (PSM antigen). - When we analyzed the other end of the molecule by reading from the N primer the sequence was:
CTC TTC GGC ATC CCA GCT TGC AAA (SEQ ID No. 32) CAA AAT TGT TCT - Since this represents the anti-sense DNA sequence, we need to show the complementary sense sequence in order to find our peptide.
- Sense Sequence:
AGA ACA ATT TTG TTT GCA AGC TGG (SEQ ID No. 33) GAT GCC AAG GAG R T I L F A S W (SEQ ID No. 34) D A E E - The underlined amino acids here represent the portion of peptide 7 used to create primer N. All of the amino acids upstream of this primer are correct in the IN-20 clone, agreeing with the amino acids found in peptide 7. Further DNA sequencing has enabled us to identify the presence of our other PSM peptides within the DNA sequence of our positive clone.
- The DNA sequence of this partial cDNA was found to be unique when screened on the Genbank computer database.
- VII. cDNA Library Construction and Cloning of Full-Length PSM cDNA
- A cDNA library from LNCaP mRNA was constructed using the Superscripts plasmid system (BRL®-Gibco). The library was transformed using competent DH5-α cells and plated onto 100 mm plates containing LB plus 100 μg/ml of Carbenicillin. Plates were grown overnight at 37° C. and colonies were transferred to nitrocellulose filters. Filters were processed and screened as per Grunstein and Hogness (26), using our 1.1 kb partial cDNA homologous probe which was radiolabelled with 32P-dCTP by random priming (27). We obtained eight positive colonies which upon DNA restriction and sequencing analysis proved to represent full-length cDNA molecules coding for the PSM antigen. Shown in
FIG. 7 is an autoradiogram showing the size of the cDNA molecules represented in our library and inFIG. 8 restriction analysis of several full-length clones is shown.FIG. 9 is a plasmid Southern analysis of the samples inFIG. 8 , showing that they all hybridize to the 1.1 kb partial cDNA probe. - Both the cDNA as well as the antigen have been screened through the Genbank Computer database (Human Genome Project) and have been found to be unique.
- VIII. Northern Analysis of PSM Gene Expression
- Northern analysis (28) of the PSM gene has revealed that expression is limited to the prostate and to prostate carcinoma.
- RNA samples (either 10 μg of total RNA or 2 μg of poly A+ RNA) were denatured and electrophoresed through 1.1% agarose/formaldehyde gels at 60 milliamps for 6-8 hours. RNA was then transferred to Nytran® nylon membranes (Schleicher and Schuell®) by pressure blotting in 10×SSC with a Posi-blotter (Stratagene®). RNA was cross-linked to the membranes using a Stratalinker (Stratagene®) and subsequently baked in a vacuum oven at 80° C. for 2 hours. Blots were pre-hybridized at 65° C. for 2 hours in prehybridization solution (BRL®) and subsequently hybridized for 16 hours in hybridization buffer (BRL®) containing 1-2×106 cpm/ml of 32P-labelled random-primed cDNA probe. Membranes were washed twice in 1×SSPE/1% SDS and twice in 0.1×SSPE/1% SDS at 42° C. Membranes were then air-dried and autoradiographed for 12-36 hours at −70° C.
- IX. PCR Analysis of PSM Gene Expression in Human Prostate Tissues
- PCR was performed on 15 human prostate samples to determine PSM gene expression. Five samples each from normal prostate tissue, benign prostatic hyperplasia, and prostate cancer were used (histology confirmed by MSKCC Pathology Department).
- 10 μg of total RNA from each sample was reverse transcribed to made cDNA template as previously described in section IV. The primers used corresponded to the 5′ and 3′ ends of our 1.1 kb partial cDNA, IN-20, and therefore the expected size of the amplified band is 1.1 kb. Since the Tm of our primers is 64° C. we annealed the primers in our PCR at 60° C. We carried out the PCR for 35 cycles using the same conditions previously described in section IV.
- LNCaP and H26—Ras transfected LNCaP (29) were included as a positive control and DU-145 as a negative control. 14/15 samples clearly amplified the 1.1 kb band and therefore express the gene.
- Experimental Results
- The gene which encodes the 100 kD PSM antigen has been identified. The complete cDNA sequence is shown in
Sequence ID # 1. Underneath that nucleic acid sequence is the predicted translated amino acid sequence. The total number of the amino acids is 750,ID 2. The hydrophilicity of the predicted protein sequence is shown inFIG. 15A . Shown inFIG. 15B are three peptides with the highest point of hydrophilicity. They are: Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 35); Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 36; and Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 37). - By the method of Klein, Kanehisa and DeLisi, a specific membrane-spanning domain is identified. The sequence is from the amino acid #19 to amino acid #44: Ala-Gly-Ala-Leu-Val-Leu-Aal-Gly-Gly-Phe-Phe-Leu-Leu-Gly-Phe-Leu-Phe (SEQ ID No. 38).
- This predicted membrane-spanning domain was computed on PC Gene (computer software program). This data enables prediction of inner and outer membrane domains of the PSM antigen which aids in designing antibodies for uses in targeting and imaging prostate cancer.
- When the PSM antigen sequence with other known sequences of the GeneBank were compared, homology between the PSM antigen sequence and the transferrin receptor sequence were found. The data are shown in
FIG. 16 . - Experimental Discussions
- Potential Uses for PSM Antigen:
- 1. Tumor Detection:
- Microscopic:
- Unambiguous tumor designation can be accomplished by use of probes for different antigens. For prostatic cancer, the PSM antigen probe may prove beneficial. Thus PSM could be used for diagnostic purposes and this could be accomplished at the microscopic level using in-situ hybridization using sense (control) and antisense probes derived from the coding region of the cDNA cloned by the applicants. This could be used in assessment of local extraprostatic extension, involvement of lymph node, bone or other metastatic sites. As bone metastasis presents a major problem in prostatic cancer, early detection of metastatic spread is required especially for staging. In some tumors detection of tumor cells in bone marrow portends a grim prognosis and suggests that interventions aimed at metastasis be tried. Detection of PSM antigen expression in bone marrow aspirates or sections may provide such early information. PCR amplification or in-situ hybridization may be used. This could be developed for any possible metastatic region.
- 2. Antigenic Site Identification
- The knowledge of the cDNA for the antigen also provides for the identification of areas that would serve as good antigens for the development of antibodies for use against specific amino acid sequences of the antigen. Such sequences may be at different regions such as outside, membrane or inside of the PSM antigen. The development of these specific antibodies would provide for immunohistochemical identification of the antigen. These derived antibodies could then be developed for use, especially ones that work in paraffin fixed sections as well as frozen section as they have the greatest utility for immunodiagnosis.
- 3. Restriction Fragment Length Polymorphism and Genomic DNA
- Restriction fragment length polymorphisms (RFLPS) have proven to be useful in documenting the progression of genetic damage that occurs during tumor initiation and promotion. It may be that RFLP analysis will demonstrate that changes in PSM sequence restriction mapping may provide evidence of predisposition to risk or malignant potential or progression of the prostatic tumor.
- Depending on the chromosomal location of the PSM antigen, the PSM antigen gene may serve as a useful chromosome location marker for chromosome analysis.
- 4. Serum
- With the development of antigen specific antibodies, if the antigen or selected antigen fragments appear in the serum they may provide for a serum marker for the presence of metastatic disease and be useful individually or in combination with other prostate specific markers.
- 5. Imaging
- As the cDNA sequence implies that the antigen has the characteristics of a membrane spanning protein with the majority of the protein on the exofacial surface, antibodies, especially monoclonal antibodies to the peptide fragments exposed and specific to the tumor may provide for tumor imaging local extension of metastatic tumor or residual tumor following prostatectomy or irradiation. The knowledge of the coding region permits the generation of monoclonal antibodies and these can be used in combination to provide for maximal imaging purposes. Because the antigen shares a similarity with the transferrin receptor based on cDNA analysis (approximately 54%), it may be that there is a specific normal ligand for this antigen and that identification of the ligand(s) would provide another means of imaging.
- 6. Isolation of Ligands
- The PSM antigen can be used to isolate the normal ligand(s) that bind to it. These ligand(s) depending on specificity may be used for targeting, or their serum levels may be predictive of disease status. If it is found that the normal ligand for PSM is a carrier molecule then it may be that PSM could be used to bind to that ligand for therapy purposes (like an iron chelating substance) to help remove the ligand from the circulation. If the ligand promotes tumor growth or metastasis then providing soluble PSM antigen would remove the ligand from binding the prostate. Knowledge of PSM antigen structure could lend to generation of small fragment that binds ligand which could serve the same purpose.
- 7. Therapeutic Uses
- a) Ligands. The knowledge that the cDNA structure of PSM antigen shares structural homology with the transferrin receptor (54% on the nucleic acid level) implies that there may be an endogenous ligand for the receptor that may or may not be transferrin-like. Transferrin is thought to be a ligand that transports iron into the cell after binding to the transferrin receptor. However, apotransferrin is being reported to be a growth factor for some cells which express the transferrin receptor (30). Whether transferrin is a ligand for this antigen or some other ligand binds to this ligand remains to be determined. If a ligand is identified it may carry a specific substance such as a metal ion (iron or zinc or other) into the tumor and thus serve as a means to deliver toxic substances (radioactive or cytotoxic chemical i.e. toxin like ricin or cytotoxic alkylating agent or cytotoxic prodrug) to the tumor.
- The main metastatic site for prostatic tumor is the bone. The bone and bone stroma are rich in transferrin. Recent studies suggest that this microenvironment is what provides the right “soil” for prostatic metastasis in the bone (31). It may be that this also promotes attachment as well, these factors which reduce this ability may diminish prostatic metastasis to the bone and prostatic metastatic growth in the bone.
- It was found that the ligand for the neu antigen (thought to be an oncogene and marker of malignant phenotype in breast carcinoma) served to induce differentiation of breast cancer cells and thus could serve as a treatment for rather than promotor of the disease. It may be that ligand binding to the right region of PSM whether with natural ligand or with an antibody may serve a similar function.
- Antibodies against PSM antigen coupled with a cytotoxic agent will be useful to eliminate prostate cancer cells. Transferrin receptor antibodies with toxin conjugates are cytotoxic to a number of tumor cells as tumor cells tend to express increased levels of transferrin receptor (32). Transferrin receptors take up molecules into the cell by endocytosis. Antibody drug combinations can be toxic. Transferrin linked toxin can be toxic.
- b) Antibodies against PSM antigen coupled with a cytotoxic agent will be useful to eliminate prostate cancer cells. The cytotoxic agent may be a radioisotope or toxin as known in ordinary skill of the art. The linkage of the antibody and the toxin or radioisotope can be chemical. Examples of direct linked toxins are doxorubicin, chlorambucil, ricin, pseudomonas exotoxin etc., or a hybrid toxin can be generated ½ with specificity for PSM and the other ½ with specificity for the toxin. Such a bivalent molecule can serve to bind to the tumor and the other ½ to deliver a cytotoxic to the tumor or to bind to and activate a cytotoxic lymphocyte such as binding to the T1-T3 receptor complex. Antibodies of required specificity can also be cloned into T cells and by replacing the immunoglobulin domain of the T cell receptor (TcR); cloning in the desired MAb heavy and light chains; splicing the Uh and UL gene segments with the constant regions of the α and β TCR chains and transfecting these chimeric Ab/TcR genes in the patients' T cells, propagating these hybrid cells and infusing them into the patient (33). Specific knowledge of tissue specific antigens for targets and generation of MAb's specific for such targets will help make this a usable approach. Because the PSM antigen coding region provides knowledge of the entire coding region, it is possible to generate a number of antibodies which could then be used in combination to achieve an additive or synergistic anti-tumor action. The antibodies can be linked to enzymes which can activate non-toxic prodrugs at its site of the tumor such as Ab-carboxypeptidase and 4-(bis(2 chloroethyl)amino)benzoyl-α-glutamic acid and its active parent drug in mice (34).
- It is possible to produce a toxic genetic chimera such as TP-40 a genetic recombinant that possesses the cDNA from TGF-alpha and the toxic portion of pseudomonas exotoxin so the TGF and portion of the hybrid binds the epidermal growth factor receptor (EGFR) and the pseudomonas portion gets taken up into the cell enzymatically and inactivates the ribosomes ability to perform protein synthesis resulting in cell death. When we know the ligand for the PSM antigen we can do the same.
- In addition, once the ligand for the PSM antigen is identified, toxin can be chemically conjugated to the ligands. Such conjugated ligands can be therapeutically useful. Examples of the toxins are daunomycin, chlorambucil, ricin, pseudomonas exotoxin, etc. Alternatively, chimeric construct can be created linking the cDNA of the ligand with the cDNA of the toxin. An example of such toxin is TGFα and pseudomonas exotoxin (35).
- 8. Others
- The PSM antigen may have other uses. It is well known that the prostate is rich in zinc, if the antigen provides function relative to this or other biologic function the PSM antigen may provide for utility in the treatment of other prostatic pathologies such as benign hyperplastic growth and/or prostatitis.
- Because purified PSM antigen can be generated, the purified PSM antigen can be linked to beads and use it like a standard “affinity” purification. Serum, urine or other biological samples can be used to incubate with the PSM antigen bound onto beads. The beads may be washed thoroughly and then eluted with salt or pH gradient. The eluted material is SDS gel purified and used as a sample for microsequencing. The sequences will be compared with other known proteins and if unique, the technique of degenerated PCR can be employed for obtaining the ligand. Once known, the affinity of the ligand will be determined by standard protocols (15).
-
- 1. Chiaroda, A. (1991) National roundtable of prostate cancer: research directions. Cancer Res. 51: 2498-2505.
- 2. Warner, J. A., et al., (1991) Future developments of non-hormonal systemic therapy for prostatic carcinoma. Urologic Clin. North Amer. 18:25-33.
- 3. Nguyen, L., et al., (1990) Prostatic acid phosphatase in the serum of cancer patients with prostatic cancer is a specific phosphotyrosine acid phosphatase. Clin. Chem. 35:1450-1455.
- 4. Henttu, P., et al., (1989) cDNA coding for the entire human prostate specific antigen show high homologies to the human tissue kallikrein genes. Bioch. Biophys. Res. Comm. 160:903-908.
- 5. Yong, C Y-F., et al., (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. 51:3748-3752.
- 6. Liotta, L. A. (1986) Tumor invasion and metastases: role of the extracellular matrix. Cancer Res. 46:1-7.
- 7. Horoszewicz, J. S., et al. (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7:927-936.
- 8. Horoszewicz, J. S., et al. (1983) LNCaP model of human prostatic carcinoma. Cancer Res., 43:1809-1818.
- 9. Lopes, D., et al. (1990) Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356, derived from anti-prostate monoclonal antibody 7E11-C5. Cancer Res., 50:6423-6429.
- 10. Wright, Jr., et al., (1990) Characterization of a new carcinoma associated marker: 7E11-C5. Antibod. Immunoconj. Radiopharm. 3:(abst#193).
- 11. Feng, Q., et al., (1991) Purification and biochemical characterization of the 7E11-C5 prostate carcinoma associated antigen. Proc. Amer. Assoc. Cancer Res. 32:239.
- 12. Axelrod, H. R., et al., Preclinical results and human immunohistochemical studies with 90Y-CYT-356. A New prostate cancer agent. Abstract 596. AUA 87th Annual Meeting, May 10-14, 1992. Washington, D.C.
- 13. Maniatis, T., et al., (1982) Molecular Cloning; Cold Spring Harbor Laboratory, pp. 197-98 (1982).
- 14. Maniatis, et al., (1982) Molecular Cloning, Cold Spring Harbor Laboratory.
- 15. Methods in Enzymology vol. 34: 1-810, 1974 (E) B. Jacoby and M. Wilchek Academic Press, New York 1974.
- 16. Hogan B. et al. (1986) Manipulating the Mouse Embryo, A Laboratory Manual, Cold Spring Harbor Laboratory.
- 17. Capecchi M. R. Science (1989) 244:1288-1292; Zimmer, A. and Gruss, P. (1989) Nature 338:150-153.
- 18. Trowbridge, I. S., (1982) Prospects for the clinical use of cytotoxic monoclonal antibodies conjugates in the treatment of cancer. Cancer Surveys 1:543-556.
- 19. Hank, S. K. (1987) Homology probing: Identification of cDNA clones encoding members of the protein-serine kinase family. Proc. Natl. Acad. Sci. 84:388-392.
- 20. Lee, C. C., et al., (1988) Generation of cDNA probes directed by amino acid sequences: cloning of urate oxidase. Science, 239, 1288.
- 21. Girgis, S. I., et al. (1988) Generation of DNA probes for peptides with highly degenerate codons using mixed primer PCR. Nucleic Acids Res. 16:10932.
- 22. Kartner, N., et al. (1977) Isolation of plasma membranes from human skin fibroblasts. J. Membrane Biology, 36:191-211.
- 23. Hsu, S. M., et al. (1981) Comparative study of the immunoperoxidase, anti-peroxidase, and avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Pathology, 75:734.
- 24. Tempst, P., et al. (1989) Examination of automated polypeptide sequencing using standard phenylisothiocyanate reagent and subpicomole high performance liquid chromatography analysis. Analytical Biochem. 183:290-300.
- 25. Birnboim, H. C. (1983) A rapid alkaline extraction method for the isolation of plasmid DNA. Meth. Enzymol, 100:243-255.
- 26. Sanger, F., et al. (1977) DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74:5463-5467.
- 27. Grunstein, M., et al. (1975) Colony hybridization as a method for the isolation of cloned DNAs that contain a specific gene. Proc. Natl. Acad. Sci. USA, 72:3961.
- 28. Feinberg, A. P., et al. (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem, 132, 6.
- 29. Rave, N., et al. (1979) Identification of procollagen mRNAs transferred to diazobenzylomethyl paper from formaldehyde gels. Nucleic Acids Research, 6:3559.
- 30. Voeller, H. J., et al. (1991) v-rasH expression confers hormone-independent in-vitro growth to LNCaP prostate carcinoma cells. Molec. Endocrinology. Vol. 5. No. 2, 209-216.
- 31. Sirbasku, D. A. (1991) Purification of an equine apotransferrin variant (thyromedin) essential for thyroid hormone dependent growth of GH1, rat pituitary tumor cells in chemically defined culture. Biochem., 30:295-301.
- 32. Rossi, M. C. (1992) Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc. Natl. Acad. Sci. (USA) 89:6197-6201.
- 33. Eshhan, Z. (1990) Chimeric T cell receptor which incorporates the anti-tumor specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutic approach. B. J. Cancer 62:27-29.
- 34. Antoniw, P. (1990) Disposition of the prodrug 4-(bis(2 chloroethyl) amino)benzoyl-α-glutamic acid and its active parent in mice. B. J. Cancer 62:905-914.
- 35. Heimbrook, D. C., et al. (1990) Transforming growth factor alpha-pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc. Natl. Acad. Sci. (USA) 87:4697-4701.
Claims (10)
1. An isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen.
2-21. (canceled)
22. A method for determining whether a ligand can bind to a mammalian prostate-specific membrane antigen which comprises contacting a mammalian cell having an isolated DNA molecule encoding a mammalian prostate-specific membrane antigen with the ligand under conditions permitting binding of ligands to the mammalian prostate-specific membrane antigen, and determining whether the ligand binds to a mammalian prostate-specific membrane antigen.
23. (canceled)
24. Purified mammalian prostate-specific membrane antigen.
25-33. (canceled)
34. An antibody directed against the amino acid sequence of a mammalian prostate-specific membrane antigen.
35. An antibody directed either to peptide Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID No. 39), or Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 39), or Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID No. 40) or Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID No. 41) of the prostate-specific membrane antigen.
36-47. (canceled)
48. A transgenic nonhuman mammal whose genome comprises antisense DNA complementary to DNA encoding a mammalian prostate-specific membrane antigen so placed as to be transcribed into antisense mRNA complementary to mRNA encoding the prostate-specific membrane antigen and which hybridizes to mRNA encoding the mammalian prostate-specific membrane antigen thereby reducing its translation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/480,319 US20070148662A1 (en) | 1992-11-05 | 2006-06-30 | Prostate-specific membrane antigen |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97333792A | 1992-11-05 | 1992-11-05 | |
US08/325,553 US5538866A (en) | 1992-11-05 | 1994-10-18 | Prostate-specific membrane antigen |
US08/481,916 US7070782B1 (en) | 1992-11-05 | 1995-06-07 | Prostate-specific membrane antigen |
US11/480,319 US20070148662A1 (en) | 1992-11-05 | 2006-06-30 | Prostate-specific membrane antigen |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/481,916 Continuation US7070782B1 (en) | 1992-11-05 | 1995-06-07 | Prostate-specific membrane antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070148662A1 true US20070148662A1 (en) | 2007-06-28 |
Family
ID=36613669
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/481,916 Expired - Lifetime US7070782B1 (en) | 1992-11-05 | 1995-06-07 | Prostate-specific membrane antigen |
US11/480,319 Abandoned US20070148662A1 (en) | 1992-11-05 | 2006-06-30 | Prostate-specific membrane antigen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/481,916 Expired - Lifetime US7070782B1 (en) | 1992-11-05 | 1995-06-07 | Prostate-specific membrane antigen |
Country Status (1)
Country | Link |
---|---|
US (2) | US7070782B1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033229A1 (en) * | 2001-10-23 | 2004-02-19 | Maddon Paul J. | PSMA antibodies and protein multimers |
US20100324008A1 (en) * | 2007-08-17 | 2010-12-23 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US20110165081A1 (en) * | 2001-10-23 | 2011-07-07 | Psma Development Company, Llc | Psma antibodies and uses thereof |
US20110189093A1 (en) * | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
USRE43586E1 (en) | 1992-11-05 | 2012-08-14 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US9242012B2 (en) | 2008-09-08 | 2016-01-26 | Psma Development Company, Llc | Methods for killing PSMA-expressing, taxane-resistant cancer cells |
US9636413B2 (en) | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US10398791B2 (en) | 2013-10-18 | 2019-09-03 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070782B1 (en) * | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
WO2009020181A1 (en) * | 2007-08-08 | 2009-02-12 | Daikin Industries, Ltd. | Multilayer body composed of fluororesin layer and elastomer layer |
EP3495000A1 (en) | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4569794A (en) * | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
US4939240A (en) * | 1983-03-04 | 1990-07-03 | Health Research, Inc. | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
US5153118A (en) * | 1985-12-17 | 1992-10-06 | Eastern Virginia Medical Authority | Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5538866A (en) * | 1992-11-05 | 1996-07-23 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US5773292A (en) * | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US5852167A (en) * | 1990-02-15 | 1998-12-22 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5855866A (en) * | 1992-03-05 | 1999-01-05 | Board Of Regenis, The University Of Texas System | Methods for treating the vasculature of solid tumors |
US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
US5935818A (en) * | 1995-02-24 | 1999-08-10 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
US5939258A (en) * | 1992-10-29 | 1999-08-17 | Thomas Jefferson University | Methods of detecting micrometastasis of prostate cancer |
US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
US5981209A (en) * | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US6017903A (en) * | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US6025344A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
US6025345A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
US6051230A (en) * | 1992-03-05 | 2000-04-18 | Board Of Regents, The University Of Texas System | Compositions for targeting the vasculature of solid tumors |
US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US6103463A (en) * | 1992-02-19 | 2000-08-15 | The Public Health Research Institute Of The City Of New York, Inc. | Method of sorting a mixture of nucleic acid strands on a binary array |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
US6136311A (en) * | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US20020019430A1 (en) * | 2000-05-30 | 2002-02-14 | Jackson Paul F. | Benzenedicarboxylic acid derivatives |
US6348464B1 (en) * | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
US6372726B1 (en) * | 1996-06-17 | 2002-04-16 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using NAALADase inhibitors |
US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
US6395718B1 (en) * | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6413948B1 (en) * | 1996-09-27 | 2002-07-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors |
US20020113295A1 (en) * | 2000-10-30 | 2002-08-22 | Ryoichi Nakamura | Semiconductor device and method for its manufacture |
US6458775B1 (en) * | 1998-07-06 | 2002-10-01 | Guilford Pharmaceutical Inc. | NAALADase inhibitors useful as pharmaceutical compounds and compositions |
US20030007974A1 (en) * | 2001-05-30 | 2003-01-09 | Nanus David M. | Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer |
US20030017965A1 (en) * | 1998-12-31 | 2003-01-23 | Slusher Barbara S. | Methods for treating certain diseases using naaladase inhibitors |
US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US20030105088A1 (en) * | 2001-01-17 | 2003-06-05 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US20040024188A1 (en) * | 1996-03-25 | 2004-02-05 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US20040120958A1 (en) * | 2001-06-01 | 2004-06-24 | Bander Neil H. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20040213791A1 (en) * | 2001-06-01 | 2004-10-28 | Neil Bander | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
US6953668B1 (en) * | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US7037647B1 (en) * | 1995-02-24 | 2006-05-02 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US7070782B1 (en) * | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US20060177450A1 (en) * | 1992-11-05 | 2006-08-10 | Israeli Ron S | Prostate-specific membrane antigen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3432714A1 (en) | 1984-09-06 | 1986-04-24 | Behringwerke Ag, 3550 Marburg | TUMOR THERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF |
CA2250141C (en) | 1996-03-25 | 2008-07-29 | Pacific Northwest Cancer Foundation | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
WO2001091738A2 (en) | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
-
1995
- 1995-06-07 US US08/481,916 patent/US7070782B1/en not_active Expired - Lifetime
-
2006
- 2006-06-30 US US11/480,319 patent/US20070148662A1/en not_active Abandoned
Patent Citations (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4939240A (en) * | 1983-03-04 | 1990-07-03 | Health Research, Inc. | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
US4569794A (en) * | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
US5153118A (en) * | 1985-12-17 | 1992-10-06 | Eastern Virginia Medical Authority | Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5852167A (en) * | 1990-02-15 | 1998-12-22 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US6103463A (en) * | 1992-02-19 | 2000-08-15 | The Public Health Research Institute Of The City Of New York, Inc. | Method of sorting a mixture of nucleic acid strands on a binary array |
US5855866A (en) * | 1992-03-05 | 1999-01-05 | Board Of Regenis, The University Of Texas System | Methods for treating the vasculature of solid tumors |
US6051230A (en) * | 1992-03-05 | 2000-04-18 | Board Of Regents, The University Of Texas System | Compositions for targeting the vasculature of solid tumors |
US20020037289A1 (en) * | 1992-03-05 | 2002-03-28 | Board Of Regents, The University Of Texas System | Combined methods and compositions for tumor vasculature targeting and tumor treatment |
US20030185832A1 (en) * | 1992-03-05 | 2003-10-02 | Board Of Regents, The University Of Texas System | Combined methods and compositions for tumor vasculature targeting and tumor treatment |
US5939258A (en) * | 1992-10-29 | 1999-08-17 | Thomas Jefferson University | Methods of detecting micrometastasis of prostate cancer |
US6953668B1 (en) * | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5538866A (en) * | 1992-11-05 | 1996-07-23 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US7070782B1 (en) * | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US20060177450A1 (en) * | 1992-11-05 | 2006-08-10 | Israeli Ron S | Prostate-specific membrane antigen |
US7105159B1 (en) * | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US20040198657A1 (en) * | 1993-11-05 | 2004-10-07 | Heston Warren D. W. | Prostate-specific membrane antigen and uses thereof |
US7037647B1 (en) * | 1995-02-24 | 2006-05-02 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US5935818A (en) * | 1995-02-24 | 1999-08-10 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
US20040001846A1 (en) * | 1995-02-24 | 2004-01-01 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US20020015704A1 (en) * | 1995-06-05 | 2002-02-07 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer |
US5773292A (en) * | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
US6962981B1 (en) * | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US20040024188A1 (en) * | 1996-03-25 | 2004-02-05 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US20030031673A1 (en) * | 1996-05-06 | 2003-02-13 | Bander Neil H. | Treatment and diagnosis of cancer |
US7163680B2 (en) * | 1996-05-06 | 2007-01-16 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US20030003101A1 (en) * | 1996-05-06 | 2003-01-02 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer |
US6136311A (en) * | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6770450B1 (en) * | 1996-05-06 | 2004-08-03 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6649163B1 (en) * | 1996-05-06 | 2003-11-18 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US7112412B1 (en) * | 1996-05-06 | 2006-09-26 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer |
US6372726B1 (en) * | 1996-06-17 | 2002-04-16 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using NAALADase inhibitors |
US5968915A (en) * | 1996-06-17 | 1999-10-19 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors |
US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
US6025344A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
US6025345A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5880112A (en) * | 1996-06-17 | 1999-03-09 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors |
US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US20020151503A1 (en) * | 1996-06-17 | 2002-10-17 | Slusher Barbara S. | Methods of cancer treatment using naaladase inhibitors |
US6479471B1 (en) * | 1996-06-17 | 2002-11-12 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
US6413948B1 (en) * | 1996-09-27 | 2002-07-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors |
US6017903A (en) * | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
US6271245B1 (en) * | 1997-04-04 | 2001-08-07 | Guilford Pharmaceuticals, Inc. | Hydroxamic acid derivatives |
US20010044459A1 (en) * | 1997-04-04 | 2001-11-22 | Jackson Paul F. | Hydroxamic acid derivatives |
US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US6288046B1 (en) * | 1997-04-24 | 2001-09-11 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US5981209A (en) * | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
US20030083374A1 (en) * | 1998-07-06 | 2003-05-01 | Jackson Paul F. | NAALADase inhibitors useful as pharmaceutical compounds and compositions |
US20030064912A1 (en) * | 1998-07-06 | 2003-04-03 | Slusher Barbara S. | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors |
US6395718B1 (en) * | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6458775B1 (en) * | 1998-07-06 | 2002-10-01 | Guilford Pharmaceutical Inc. | NAALADase inhibitors useful as pharmaceutical compounds and compositions |
US20030017965A1 (en) * | 1998-12-31 | 2003-01-23 | Slusher Barbara S. | Methods for treating certain diseases using naaladase inhibitors |
US6348464B1 (en) * | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
US6452044B2 (en) * | 2000-05-30 | 2002-09-17 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
US20020019430A1 (en) * | 2000-05-30 | 2002-02-14 | Jackson Paul F. | Benzenedicarboxylic acid derivatives |
US20020113295A1 (en) * | 2000-10-30 | 2002-08-22 | Ryoichi Nakamura | Semiconductor device and method for its manufacture |
US20030105088A1 (en) * | 2001-01-17 | 2003-06-05 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US20030216468A1 (en) * | 2001-01-17 | 2003-11-20 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US6586623B2 (en) * | 2001-01-17 | 2003-07-01 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US20030007974A1 (en) * | 2001-05-30 | 2003-01-09 | Nanus David M. | Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer |
US20040213791A1 (en) * | 2001-06-01 | 2004-10-28 | Neil Bander | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20040120958A1 (en) * | 2001-06-01 | 2004-06-24 | Bander Neil H. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43586E1 (en) | 1992-11-05 | 2012-08-14 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US8470330B2 (en) | 2001-10-23 | 2013-06-25 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
US20080286284A1 (en) * | 2001-10-23 | 2008-11-20 | Psma Development Company, Llc | Compositions of PSMA antibodies |
US7850971B2 (en) | 2001-10-23 | 2010-12-14 | Psma Development Company, Llc | PSMA antibodies and protein multimers |
US9695248B2 (en) | 2001-10-23 | 2017-07-04 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
US20110165081A1 (en) * | 2001-10-23 | 2011-07-07 | Psma Development Company, Llc | Psma antibodies and uses thereof |
US20040033229A1 (en) * | 2001-10-23 | 2004-02-19 | Maddon Paul J. | PSMA antibodies and protein multimers |
US8114965B2 (en) | 2001-10-23 | 2012-02-14 | Psma Development Company, Llc | Compositions of PSMA antibodies |
US11504357B2 (en) | 2007-08-17 | 2022-11-22 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10046054B2 (en) | 2007-08-17 | 2018-08-14 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9193763B2 (en) | 2007-08-17 | 2015-11-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10624969B2 (en) | 2007-08-17 | 2020-04-21 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11717514B2 (en) | 2007-08-17 | 2023-08-08 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US20100324008A1 (en) * | 2007-08-17 | 2010-12-23 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US10624971B2 (en) | 2007-08-17 | 2020-04-21 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11369590B2 (en) | 2007-08-17 | 2022-06-28 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11318121B2 (en) | 2007-08-17 | 2022-05-03 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US8907058B2 (en) | 2007-08-17 | 2014-12-09 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11298341B2 (en) | 2007-08-17 | 2022-04-12 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11083710B2 (en) | 2007-08-17 | 2021-08-10 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10406240B2 (en) | 2007-08-17 | 2019-09-10 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10828282B2 (en) | 2007-08-17 | 2020-11-10 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10485878B2 (en) | 2007-08-17 | 2019-11-26 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10517956B2 (en) | 2007-08-17 | 2019-12-31 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10517957B2 (en) | 2007-08-17 | 2019-12-31 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10646581B2 (en) | 2007-08-17 | 2020-05-12 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10624970B2 (en) | 2007-08-17 | 2020-04-21 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US20110189093A1 (en) * | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
US9242012B2 (en) | 2008-09-08 | 2016-01-26 | Psma Development Company, Llc | Methods for killing PSMA-expressing, taxane-resistant cancer cells |
US10557128B2 (en) | 2010-02-25 | 2020-02-11 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11155800B2 (en) | 2010-02-25 | 2021-10-26 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10912840B2 (en) | 2012-11-15 | 2021-02-09 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US9782493B2 (en) | 2012-11-15 | 2017-10-10 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US9636413B2 (en) | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US11045564B2 (en) | 2013-10-18 | 2021-06-29 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer |
US10398791B2 (en) | 2013-10-18 | 2019-09-03 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US10471160B2 (en) | 2013-10-18 | 2019-11-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US11931430B2 (en) | 2013-10-18 | 2024-03-19 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer |
US11951190B2 (en) | 2013-10-18 | 2024-04-09 | Novartis Ag | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer |
US10918741B2 (en) | 2014-01-24 | 2021-02-16 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
US10898596B2 (en) | 2015-01-07 | 2021-01-26 | Endocyte, Inc. | Conjugates for imaging |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
Also Published As
Publication number | Publication date |
---|---|
US7070782B1 (en) | 2006-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5538866A (en) | Prostate-specific membrane antigen | |
US20070148662A1 (en) | Prostate-specific membrane antigen | |
USRE43586E1 (en) | Antibodies to prostate-specific membrane antigen | |
US6953668B1 (en) | Prostate-specific membrane antigen | |
US7037647B1 (en) | Prostate-specific membrane antigen and uses thereof | |
US5935818A (en) | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof | |
US7008765B1 (en) | PCA3, PCA3 genes, and methods of use | |
US20100303715A1 (en) | Prostate-specific membrane antigen and uses thereof | |
EP2064550B1 (en) | Use of prrg4 in methods of tumor diagnosis | |
EP0804451A1 (en) | Lung cancer marker | |
JP3779989B2 (en) | Lymphoid antigen CD30 | |
WO1998011136A1 (en) | A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS | |
EP0894131A1 (en) | Human hyaluronan receptor | |
EP1209231A1 (en) | Meg-1 protein | |
CA2193315A1 (en) | Human mucin (muc8) | |
WO2003029818A2 (en) | Methods and animal models for tumor formation involving dutti | |
JP2001340081A (en) | Human pancreatic cancer antigen | |
WO2000066729A1 (en) | Meg-3 protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |